10KSB 1 sep_10k.txt FORM 10KSB FORM 10-KSB SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2001 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 1-14068 SEPRAGEN CORPORATION ---------------------------------------------- (Name of small business issuer in its charter) California 68-0073366 ------------------------------- ------------------- (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 14500 Doolittle Drive, San Leandro, California 94577 ---------------------------------------------------- (Address of principal executive offices, zip code) Issuer's telephone number: (510) 667-1004 Securities registered pursuant to Section 12(b) of the Exchange Act: CLASS A COMMON STOCK, no par value; ----------------------------------- (Title of Class) Securities registered pursuant to Section 12(g) of the Exchange Act: None. Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ] Check if there is no disclosure of delinquent filers in response to Item 405 of Regulation S-B contained in this form, and no disclosure will be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-KSB or any amendment to this Form 10-KSB. Issuer's revenues for its most recent fiscal year were: $1,153,953. The aggregate market value of Class A Common Stock (voting stock) held by non-affiliates on March 29, 2002 was $2,334,000 (based on the average of the last bid and ask price of a share of Class A Common Stock on that date as reported in Over The Counter trading). In addition, non-affiliates held 67,413 shares of Class B Common Stock as of March 22, 2002, which are convertible into Class A Common Stock, but are not registered under the Securities Exchange of 1934, as amended. The number of shares outstanding of each of the registrant's classes of Common Stock at March 29, 2002 was: Class A Common Stock 10,972,398 Class B Common Stock 701,177 In addition, the Company has 175,439 shares outstanding of convertible preferred stock convertible into Class A Common Stock. Class E Common Stock became subject to mandatory redemption as of March 31, 2000 and a notice of redemption designated the effective date of June 15, 2000. The Company's Class A and Class B Warrants expired on March 23, 2000. Transitional Small Business Disclosure Format [ ] Yes; [X] No Page 1 PART I ------ Item 1. Description of Business ------ ----------------------- Company Overview Sepragen, incorporated in 1985, is a provider of innovative high throughput equipment, systems and materials for the scale-up and purification of proteins, biopharmaceuticals and nutraceuticals. In the biopharmaceutical industry, with the elucidation of the human genome in the last 24 months and the advent of high throughput discovery and screening tools, the industry can rapidly transition from identifying a gene responsible for a disease state to the protein based drug candidate or associated target molecules and lead therapeutic drug compounds. The number of such targets and drug candidate leads are increasing rapidly and we believe that the demand for our technology adapted to producing quantitative amounts of these products for preclinical or clinical studies is increasing. We have responded to this growing need with the QuantaSep product line, which automates many routine chromatographic purification tasks. The automated QuantaSep improves process development time and speeds preparation time for clinical trials.. In addition, our patented Radial Flow Chromatography (RFC) technology enables purification of greater quantities of product more efficiently than conventional chromatography methods and provides a measurable economic advantage. Sepragen's products are currently being used at leading biotech/pharmaceutical companies such as Amgen, Bayer, Chiron, Baxter, Human Genome Sciences, and Schering-Plough to produce FDA approved drugs in commercial scale quantities and for other drugs that are in clinical development. We are building on these early successes and are supplying premier scalable chromatography tools, processes, and technologies for the scale-up of biopharmaceutical products from the laboratory to commercial production volume levels. During the past five years, the Company has also developed specific applications of separations technology for the nutraceautical industry. The Sepralac (TM) process isolates high value proteins from relatively low-value whey, a liquid byproduct of cheese production. Whey currently sells for approximately 50 cents a kilogram and is typically dried and processed into saleable products for human consumption or for animal feed. The Company licenses the process for isolation of proteins in the whey for utilization in infant formula and other products for their nutritional, functional and, in some cases, pharmaceutical value. These proteins can be used to manufacture a human infant formula that more closely resembles the protein composition of mothers' milk and protein-based fat or egg white substitute. Individual components within the whey are valued at over $400 per kilogram. Sepragen has signed commercialization agreements with two leading dairy ingredient suppliers - Anchor Products of New Zealand and Carbery Milk Products of Ireland. Both companies have paid licensing fees and are obligated to purchase equipment and consumables from Sepragen and pay us a royalty on sales as they increase their commercial efforts. While the Company has commercial activities in both the biopharmaceutical and nutraceutical markets, its current resources are primarily focused on direct marketing and support activities in the biopharmaceutical sector. The Company is secondarily pursuing alliances and other financing activities as a means of expanding its primary market and commercializing its technology portfolio in the nutraceutical industry. Our ability to successfully commercialize and derive value from these opportunities will depend on our ability to secure additional funding to expand our sales, marketing, support and manufacturing infrastructure and to convince risk-averse personnel in a regulated, pharmaceutical environment to adopt our products. In the nutraceutical industry it may require us to enter into more alliances such as the ones that the Company has with Anchor Products and Carbery Milk Products. No assurance can be provided that the Company or its current or future alliance partners will be successful at each of these endeavors. Page 2 Biopharmaceutical Market The biotech industry's revenues have topped $28 billion and growth is accelerating with 300 products presently in late stage clinical development and 1,200 more in early stage clinical or pre-clinical testing. Additionally, with the sequencing of the human genome coupled with improvements in proteomics, the drug discovery process has become efficient and productive. More and more lead compounds are being generated. We believe that this increase in drug leads is necessitating an expansion of development, scale-up and manufacturing capacity to clinically test and develop promising drug product candidates. The current discovery and commercialization process in comprised of the following basic steps: 1) genomics gene analysis 2) proteomics 3) screening protein and modulators for activity, 4) preparation of small quantities for proof concept 5) pre-clinical development tests, 6) Phase I, II and III clinical trials 7) FDA approval and 8) commercialization and post approval monitoring. Sepragen's products provide for the rapid purification of biopharmaceuticals from the proof of concept stage up through commercial scale manufacturing. The existing infrastructure in the biopharmaceutical industry, we believe, is insufficient and bottlenecks will appear in process development, scale-up and manufacturing. According to a recent J.P. Morgan research note - "The State of Biologics Manufacturing" - clinical and commercial manufacturing capacity demand is expected to outstrip available capacity by a ratio of four-to-one. The manufacturing bottleneck issue is endemic to the industry, which has focused more on research and clinical applications then on commercial manufacturing. The seriousness has been highlighted recently by Immunex's reported inability to satisfy market needs for Enbrel, their billion-dollar flagship product, due to a major shortfall in capacity. A single new facility is expected to take four years for installation and validation at a cost of up to $400 million. Management believes that the elucidation of the human genome has resulted in a new growth and market opportunity for research lab to pilot scale preparation of pharmaceutical proteins and drugs necessary for proof of concept and early clinical trials. As drug discovery and gene analysis at the R&D level has increased greatly in sophistication and efficiency over the last decade, there is an increasing number of newly discovered drug candidates and proteins that need to be rapidly and reproducibly purified. Sepragen has addressed this growing segment of the biopharmaceutical market with the QuantaSep series of automated chromatography instruments that facilitate the efficient and reproducible chromatographic purifications from laboratory scale through pilot scale and continuing up to commercial scale. Helping our existing `fast-track' customers process their lead drug compounds efficiently and enable faster time to market is our focus. We are establishing our own direct sales and service capabilities and are expanding and adding more technological depth and breadth to the QuantaSep and consumable product lines. This will require additional capital and reliance on a few key people. No assurance can be given that the funds will be raised nor that this initiative will be successful. While no assurances can be provided that the industry will "scale-up" with our technology, the opportunity exists that, given adequate resources and the continued capacity crunch, Sepragen can play a role in providing the industry with enabling products and technology for its infrastructure needs in development, scale-up and manufacturing. Product Overview Sepragen has an array of technologies and products that address the production of protein and gene-based biological drugs. Sepragen's patents cover composition of matter and process claims related to its equipment and consumable resins used in separations. Core to these proprietary technologies is Sepragen's patented Radial Flow Chromatography and consumable monolith and rigid consumable resins, all high throughput bio-purification products that enable cost effective volume processing in its target markets. The QuantaSep Automated Purification System which provides robust instrumentation with user-friendly software for control and documentation of chromatography processes, is the standard `anchor' workstation that is the base of our technology portfolio. Page 3 Chromatography Technologies --------------------------- Radial Flow Chromatography Columns Chromatography is the principal method used for bio-purification in the Biopharmaceutical and Nutraceutical industries. Chromatography separates selected molecules in pure form from an impure mixture, based upon selective extraction and release of the product in a `column' chamber packed with a special adsorbent. Thus, the desired molecules are separated from raw materials, which are then processed and packaged into marketable products. The liquid volume and product amount processed in a certain time per volume of adsorbent represents the measure of productivity. Conventional chromatography or `Axial Chromatography' uses a long vertical flow path through the column that results in reduction in flow as the height of the column, or scale, is increased. Sepragen's patented Radial Flow Chromatography (RFC) technology enables horizontal flow across the radius of the column. The resulting RFC productivity performance is several-fold higher than conventional axial means and, in fact, RFC gains in productivity as the scale is increased. In one instance, over 40,000 liters of human plasma is being treated every 6 hours on 2,800 liters of Sepragen columns to produce kilograms of an FDA approved injectable protein drug per batch. We believe this unique capability for high productivity performance will continue to rise in demand as the biopharmaceutical and nutraceutical industries mature into high volume production looking for the lowest-cost, most efficient and scalable manufacturing methods. Sepragen's products allow trained process development chromatography scientists and engineers to optimally design the most scalable, economic and reliable process and enable rapid time to market. In Radial Flow Chromatography, liquid flows from a perimeter sleeve surrounding the columnar resin bed and horizontally across the permeable resin into a small hollow cylinder exit port at the center. Flow rates through the RFC column are higher than with axial chromatography , allowing economical processing of large volumes of material. In the processing of liquid foods or beverage products, the result can be economic separation of specific substances that have higher nutritional economic or product quality value. Additionally, large-scale RFC facilitates economical removal of unwanted substances that adversely affect flavor or other product qualities. In the biopharmaceutical industry, Radial Flow Chromatography is being used to manufacture twelve FDA approved drugs, including Baxter's IVIG, Amgen's Nupogen and Bayer's Kogenate. Radial Flow Chromatography also received the prestigious IR100 Award as one of the most innovative products of the year in 1989. In the nutraceutical industry, Sepragen's RFC system is being used by Anchor products and Carbery Milk Products to isolate several proteins from dairy whey for use in infant formula and nutritional supplement products. Sepragen's patented Superflo(TM) radial flow columns allow high throughput at low pressures and range in size from 50 ml to 350 liter columns.Our columns allow easy downscaling or upscaling. Our Versaflo(TM) traditional axial flow columns expand the usage of Sepragen's product line to lower volume quantities during the final purification process. Sepragen's RFC columns are available with accessories in acrylic and stainless steel construction. Average gross margins on columns are about 50% and prices range from $1,000 for laboratory scale experimental units to over $150,000 for larger production units. QuantaSep Chromatography Instrumentation QuantaSep Chromatography Systems - For Lab, Pilot and Production Stages The QuantaSep(TM) product line enables customers to automate and speed-up routine tasks in chromatographic purification of lead ing product candidates, improve product consistency, and provide better data for regulatory purposes leading to faster time to market and lower clinical development and production costs. The QuantaSep(TM) instrument series achieves higher production rates within less than 50% of the footprint of competing systems. These compact systems, driven by of Sepragen's proprietary software, sensors and fluid delivery modules, are workhorses that are currently being used by leading companies such as IDEC, Human Genome Sciences, Berlex and Schering Plough to develop, process and produce clinical grade products. The QuantaSep(TM) Systems are available in Models QuantaSep(TM) 100, QuantaSep(TM) Page 4 1000, QuantaSep(TM) LX, and QuantaSep(TM) 1800, that provide flow ranges between 100 mls per minute and 1.8 liters per minute. Those flow ranges allow the Company to offer products for all stages of drug development and production. Fully installed prices range from $65,000 to approximately $150,000. There are over 50 installations of these systems currently in use. QuantaSep 5000 We have previously developed a custom large scale QuantaSep capable of delivering flow rates of up to 40 liters/minute. This technology is now being standardized in a QuantaSep 5000 product capable of delivering 5 liters/minute. The QuantaSep 5000 is designed to provide our customers with a scalable path using the same software, sensors and design parameters used in their lab experiments to transition to the pilot plant and prepare GMP production lots for clinical trials. This machine can be used to automate and control manufacturing processes in the biopharmaceutical industry or for pilot scale evaluations in food applications. It brings all the process features of the QuantaSep 100 to 1800 series to pilot-scale and large-scale use and brings the QuantaSep advantages to manufacturing. Chromatography, and Sepragen's High Throughput Resins Resins are used with our equipment and need to be replaced several times per year, depending on the application and volume. Sepragen has developed high throughput consumable resin products for several applications and are expected to be a source of recurring revenue in our razor and razor-blade business model. A novel monolith resin technology capable of rapid upfront capture of selected product molecules from dilute solutions has been developed and patented. High throughput durable rigid bead technology has also been developed. SepraPrep(R) For high volume biotech applications, the Company has developed a beaded, high-strength, high-flow, hydrophilic, ion-exchange media "SepraPrep(R)." The material is currently in use in Sepragen's Sepralac(TM) Process to isolate and produce whey proteins on a commercial scale. Once data is developed for a variety of biotech applications, this media can also be marketed to the biotech customer base. SepraSorb(R) Media The SepraSorb(R) Media is based in part upon technology acquired in the purchase in June 1994 of certain assets of BPS Separations, a U.K. company. The SepraSorb(R) media is based on a "sponge" as opposed to a "bead" configuration. The unique ability of the SepraSorb(R) media to handle "dirty streams" without clogging will eliminate various pre-clearing chromatography steps and increase overall yield and productivity of many purification processes. SepraSorb(R) cartridges are being sold to the biopharmaceutical market for research and lab evaluation use. While the technology and market opportunity has promise, both these product lines will require additional development, applications support and marketing resources prior to serious commercial launch. No assurance can be provided that we will be successful in securing the funds or that the products will be accepted across the board by the industry. Customers Sepragen's products or tools are currently in use for commercial scale manufacture of over twelve FDA approved drugs including Kogenate(R), Alphanate(R), Neupogen(R), and GammaGrand(R). The Company's QuantaSep series of instruments are also in use with a multitude of other drugs currently in preclinical and clinical trials. Sepragen's customers range from manufacturers of recombinant proteins and peptides, pharmaceutical drugs and derivatives, vaccine manufacturers, Page 5 genetic therapy vectors, monoclonal antibody producers for diagnostic and therapeutic use and enzyme producers. The Company's international list of customers in the U.S., Europe, and Asia includes:
Amgen Chiron Corp Human Genome Sciences, Inc. Alpha Therapeutics Chugal IDEC Pharmaceuticals Asahi Glass CSL Merck & Co Aventis S.A., Dade Behring Roche Molecular Systems Avigen Eli Lilly Schering Plough Bayer Glaxo SmithKline Yoshitomi Baxter International Inc. Genencor International Inc. Berlex Hoffman La Roche
In 2001 approximately 70% of sales revenues were from sales to customers in the United States and 30% to customers outside the United States. All of our 2001 sales revenues were attributable to biotech sector sales. Our future growth and profitability in the biopharmaceutical sector will depend, in large part, on the rate of scale-up activities in this market and in fostering acceptance of the use of our products, namely Superflo(R) columns, QuantaSep systems and SepraSorb resins. Negotiating joint ventures and alliances in the dairy, food, and beverage industries is expected to drive our growth in those segments. Our success in marketing our products will be substantially dependent on educating our targeted markets as to the distinctive characteristics and benefits of our products and technology. There can be no assurance that our efforts or the efforts of others with whom we ally ourselves will be successful, or that our products will ever achieve the level of sales necessary for us to operate profitably. Food and Beverage Industry We believe our RFC technology can be used to develop a broad range of high volume processes in the food and beverage industry. RFC allows the production of substantially pure compositions of molecules that have nutritional or other value and the removal of substances from various foods and beverages that have been identified as harmful or that adversely affect flavor or other qualities. In many cases, processes for separating and purifying or removing these molecules are either not currently available or require relatively high levels of capital investment and ongoing operating expenses. Separating the Components of Whey. We have developed a process called Sepralac(TM) for separating and purifying the components of whey, a by-product of cheese production. The whey is the liquid part of the milk remaining after the curds used for the cheese have formed and been separated. A substantial portion of the liquid whey is dried and processed into salable products for human consumption or as animal feed. The remainder of the whey is disposed of as waste. Whey is comprised of several different components which in their pure form have nutritional, functional and, in some cases, pharmaceutical value. Whey sells for approximately 50 cents a kilogram, but individual components within the whey are valued at over $400 per kilogram. Conventional processing technologies do not allow for economic separation and purification of each of the components of the whey. As a result, whey is used currently in dry form in whey protein concentrate ("WPC") and whey protein isolate ("WPI"). WPI is a recent product introduction indicating an industry trend towards higher value, higher purity and higher protein content products. WPC and WPI are used in infant formula, foods, soups, beverages and confectionery and bakery products for their nutritional and functional properties including emulsification, foaming and gelling. These properties can be improved if certain protein components are either isolated in a pure form or removed, depending on certain factors. For example, fat contained in WPC reduces foamability which is a desired property in ice creams, shakes and bakery products. Using Sepragen's Sepralac(TM) process, we believe individual whey components can be separated more economically. The Company believes the isolated components can be used in a variety of applications to produce improved end products or entirely new products. There can be no assurance that commercial applications for whey proteins isolated using the Company's Sepralac(TM) process can be found, or that such proteins can be sold at prices in excess of the costs of development. Page 6 Humanized Infant Formula. Commercial infant formula is made from WPC and WPI which is fortified with vitamins and minerals. Compared to human milk, the protein composition of this formula contains certain undesirable components while other desirable components are present in very small quantities. We believe that having access to certain protein components that can be separated using the Sepralac(TM) process will give infant formula manufacturers the ability to produce infant formula that more closely resembles the protein composition of human milk. Other Whey Applications. Having the ability to separate the individual proteins in the whey potentially creates additional applications for those proteins. Certain protein components could be added to sports drinks to improve nutritional value without "curdling" or "precipitating." Certain protein components could replace egg whites since they provide better whippability and gelation characteristics. Additional applications for protein components include geriatric products where a specialized nutritional profile is desired, meat products where enhanced binding is required and ice creams and shakes where increased whippability is desired. Debittering Citrus Juice. We have successfully demonstrated a process called Sepradebitt(TM) to debitter and deacidify citrus juice. A patent was issued in 1998. In 1999, we began to introduce the process to juice processors for their evaluation. No revenues have been generated from sales of such processes to date. Orange processing in both California and Florida results in unsqueezed juice that is too bitter to use. If processors could use all of the juice in the orange, not just that obtained in the first squeeze, their economics would improve. Additionally, oranges grown in California go through a period of months when they are too bitter to be processed into juice. Similarly, the bitterness of grapefruit juice prevents its use as an ingredient in mixed juice production. Debittering grapefruit juice may extend its usage to new applications. We have only recently begun to introduce the process to juice processors for their evaluation and no revenues have been generated from the sale or license of this process to date. Soy Isoflavone Isolation Our Company has developed a proprietary RFC based process to purify isoflavones from a soy-based raw material. We have named this process "Sepraflavone" and we believe that soy isoflavones are desirable as health enhancing dietary supplements. Our research indicates that our process will enable a manufacturer to make purer product with consistent quality. However, no assurance can be given that we will be successful in commercially developing the Sepraflavone process. Nutraceutical Business Model and Alliances Our intended business model in the nutraceutical industry for these proprietary processes is to include royalties and licensing fees, in addition to equipment and resin revenues. We have licensed the Sepralac(TM) process to Anchor Products of New Zealand and Carbery Milk Products of Ballineen, Ireland. While there are on-going discussions for alliances with potential partners for the Sepralac (TM) , SepraDebitt (TM) and other projects, no assurance can be given that these will materialize or be commercial successes. Page 7 Manufacturing and Supplies Third party contract manufacturers produce the components for our products. We assemble the products and perform quality control. We intend to continue to enter into additional arrangements with third parties to manufacture the components of our products according to specifications provided by us. For example, we have an agreement with a supplier headquartered in India to manufacture certain of our ion-exchange resins. We continue to monitor production at these manufacturing facilities to assure compliance with product specifications. In January 1999, we also entered into an exclusive five-year agreement with a vendor to supply certain column parts and accessories. While these agreements allow us to command more attention from our critical vendors, they also create a "single source" risk if the vendors are unable to meet the quality or delivery needs of our customers. There can be no assurance that we will be able to enter into future arrangements, on acceptable terms or at all, for the manufacture of our products by others or that any manufacturer will be able to meet any demand for such products on a timely or cost effective basis. We are currently relying and intend to continue to rely on certain suppliers to provide substantially all of the materials required to produce our products, including, but not limited to, fabricated steel, plastics, wiring, circuitry and computer hardware. We have been and expect to continue to be able to obtain all materials needed for these purposes without any significant interruption or sudden price increase, although there can be no assurance thereof. The raw materials utilized in the manufacture and assembly of our products are readily available from a wide variety of industry sources. In the future, we may decide to manufacture directly certain of our existing or proposed products. Manufacture of these products will require expensive equipment and experienced personnel. Although certain of our officers have had manufacturing experience with other companies, we have limited manufacturing experience and capabilities. There can be no assurance that we will be able to obtain the requisite financing, attract or retain experienced personnel or be able to establish a suitable manufacturing facility. Research and Development We spent approximately $547,000 and $673,000 on research and development for the years ended December 31, 2001 and 2000, respectively. Substantially all of our research and development expenditures to date have been related to our QuantaSep systems and Sepralac(TM) and Seprabitt processes. We maintain an on-going research and development program that targets: (i) improvements and extensions of existing products which exploit our patents to address specific customer needs; (ii) continued development of separation media; and (iii) continued development of commercial-scale liquid chromatography processes based on RFC technology for food and dairy applications. Patents, Trademarks and Intellectual Property We consider patent protection of our processes to be important to our business prospects. We currently hold fifteen patents and one allowed patent application in the United States relating to our technologies. In addition, we hold nine patents in various foreign countries. Page 8 The first of our patents was issued in 1986 for our radial flow processes and method relating to purification columns. Since then, we have successfully obtained patents for various other technologies. Our patents are issued for the following inventions and have the expiration dates indicated (assuming all required maintenance fees are paid): o U.S. Patent Reg. Nos. 4,627,918 (11/4/2005); 4,676,898 (11/4/2005); 4,840,730 (11/4/2005) and 4,865,729 (11/4/2005) cover different horizontal or radial flow chromatography methods and apparatuses. o U.S. Patent Reg. No. 5,462,659 (6/15/2013) covering axial flow chromatography columns. o U.S. Patent Reg. No. 4,708,782 (9/15/2006) covers a combination horizontal or radial flow chromatography column and electrophoresis apparatus. o U.S. Patent Reg. No. 4,867,947 (9/19/2006) covers interface apparatuses for directing the output of a chromatography column to a point of use/detection and/or identification such as a mass spectrometry device o U.S. Patent Reg. No. 4,705,616 (9/15/2006) covers a combination electrophoresis/ mass spectrometry probe for performing the two processes of electrophoretic separation of a sample followed by introduction of the separated sample to a mass spectrometry apparatus. o U.S. Patent Reg. No. 4,833,083 (11/04/2005) covers a packed bed bioreactor for anchorage or nonanchorage dependent cells, or for immobilized enzymes, that is capable of achieving high cell densities or concentrations of reaction products. o U.S. Patent Reg. No. 5,492,723 (2/20/2013) covers a method of producing a cross-linked flexible sponge adsorbent medium. o U.S. Patent Reg. No. 5,597,489 (3/02/2015) covers a method for removing contaminants from water. o U.S. Patent Reg. No. 5,690,996 (11/2/2012) covers absorbent medium. o U.S. Patent Reg. No. 5,756,680 (1/5/2014) covers a method for sequential separation of whey proteins and formulations. o U.S. Patent Reg. No. 5,817,354 (8/22/2016) covers a method for removing bitter compounds from citrus juice. o U.S. Patent Reg. No. 6,045,842 (8/22/2016) covers a method for high throughput debittering of Limonin. We intend to continue to pursue patent protection for the various technologies we develop. There can be no assurance that any of our issued patents will afford protection against a competitor, that any patents issued or licensed to us could not be designed around or invalidated or that our pending patent applications will result in issued patents. In addition, there can also be no assurance that any application of our technology will not infringe patents or proprietary rights of others or that licenses that might be required for our processes or products would be available on reasonable terms. Furthermore, there can be no assurance that challenges will not be instituted against the validity or enforceability of any patent owned by us or, if instituted, that such challenges will not be successful. The cost of litigation to uphold the validity and prevent infringement can be substantial. We believe that patents in certain foreign countries are more difficult and expensive than obtaining domestic patents because of differences in patent laws, and recognizes that our patent position therefore may be stronger in the Page 9 United States than abroad. In addition, the protection provided by foreign patents, once they are obtained, may be weaker than that provided by domestic patents, with the attendant risks of infringement of our patents and loss of market share to infringing competition. We also rely upon unpatented proprietary technology, and in the future may determine in some cases that our interest would be better served by reliance on trade secrets or confidentiality agreements rather than patents. No assurance can be given that others will not independently develop substantially equivalent proprietary information and techniques or otherwise gain access to such proprietary technology or disclose such technology or that we can meaningfully protect our rights in such unpatented proprietary technology. To the extent that consultants or other third parties apply technological information independently developed by them or by others to our projects, disputes may arise as to the proprietary rights to such information which may not be resolved in our favor. Our name, helix logo, "S" and Design, Superflo and QuantaSep trademarks are registered on the Principal Register of Trademarks maintained by the U.S. Patent and Trademark Office, and an application to register the mark Sepralac is pending. Competition We face significant competition in three principal areas of our business. With respect to our liquid chromatography equipment, resins and systems, competitors are companies that make liquid chromatography equipment and systems and companies that make separation and purification equipment and systems that compete with liquid chromatography. In the market for liquid chromatography equipment and systems, our major competitors are Amersham BioSciences, Millipore, Pall Filtration, Bio-Rad., in-house development by customers' engineering staff, and a number of smaller companies. With respect to our liquid chromatography processes under development for application in the food and dairy industries, we will face competition from existing producers of whey and other food ingredients who are attempting to develop existing separation technology for fractionating dairy ingredients. Such competitors include overseas companies such as Danmark Protein, and companies such as Immucell Corporation and Davisco International Incorporated in the United States. In addition, we may face competition from companies in the chromatography equipment industry such as Millipore and Amersham to the extent the dairy and food industries begin using chromatography separation processes in the future and from companies providing competing technologies, such as membrane filtration and ion exchange, including Koch filtration Products, Calgon Carbon Corporation, Ionics and Osmonics, Inc., which are currently used in food separation processes. Employees As of March 30, 2002, we employed a staff consisting of 16 full-time and two part-time employees and several contractors and consultants. In order to maximize the efficiency of this small staff, most employees serve in various functions as different needs arise. We have not experienced any strikes or work stoppages and consider our relationship with our employees to be satisfactory. Our employees are not covered by any collective bargaining agreement. We intend to add additional employees on an as needed basis in the areas of research, production, development, marketing, sales and administration. Our future success is substantially dependent on our ability to attract and retain highly competent technical and administrative personnel. Item 2. Description of Property ------ ----------------------- The Company moved from its Hayward facility to San Leandro, California in January 2001. The San Leandro facility is approximately 19,000 square feet. Of this space, approximately 12,000 square feet is allocated to manufacturing, approximately 2,000 square feet to the Company's laboratories, and approximately 5,000 square feet to the Company's executive and administrative offices. The term of the lease is for five years beginning on January 1, 2001. Page 10 Item 3. Legal Proceedings ------ ----------------- Neither the Company nor our officers or directors are parties to any pending legal proceedings involving a matter the outcome of which is expected to have a material adverse effect on our financial position or results of operations. Item 4. Submission of Matters to a Vote of Security Holders ------ --------------------------------------------------- No matter was submitted to a vote of security holders during the Company's fiscal year ended December 31, 2001. Page 11 PART II ------- Item 5. Market for Common Equity and Related Stockholder Matters. ------ -------------------------------------------------------- (a) Market Information. ------------------ Our IPO Units, Class A Common Stock, Class A Warrants and Class B Warrants were quoted on NASDAQ Small Cap Market from March 23, 1995 until August 15, 1997. Our Class A Common Stock is now quoted on the OTC Bulletin Board (under the symbol SPGNE.OB). Our securities were delisted from the NASDAQ Small Cap Market in 1997 because we failed to meet total asset and minimum share price requirements for continued listing. The high and low bid prices for the Class A Common Stock as reported by the OTC Bulletin Board are indicated below. Such prices are interdealer prices without markups, markdowns or commissions, and may not necessarily represent actual transactions. On March 23, 2000, the Class A and Class B Warrants (under symbols SPGNW and SPGNZ) expired. Class A Common Stock ------------ Low High 2001 First Quarter $0.16 $0.50 Second Quarter 0.17 0.40 Third Quarter 0.20 0.55 Fourth Quarter 0.16 0.40 2000 First Quarter $0.56 $3.44 Second Quarter 0.81 2.00 Third Quarter 0.56 0.88 Fourth Quarter 0.12 0.44 As of March 29, 2002, the last sale price as reported on the OTC Bulletin Board for the Class A Common Stock was $0. 20 There are no public markets for Class B Common Stock or Series A Preferred Stock. Beginning on March 31, 2000, Class E Common Stock became subject to mandatory redemption at $0.01 per share and was no longer outstanding as of June 15, 2000. (b) Holders. As of March 29, 2002, there were 67 record holders of Class A Common Stock, and 49 record holders of Class B Common Stock. The majority of the outstanding shares of Class A Common Stock are held of record by nominee holders on behalf of a number of ultimate beneficial owners which the Company has been informed exceeds 500. (c) Dividends. We have never paid any cash dividends on our Common Stock and we do not anticipate that we will do so in the foreseeable future. On November 3, 1997, we completed a private placement of 54 bridge units consisting of promissory notes and Class C warrants issued by us. No underwriter was used in the bridge unit offering, however, Dakin Securities Corporation acted as placement agent, and was paid $43,200 of which $35,000 was a commission and $8,200 was credited as a retainer for future services. Each unit consists of a bridge note in the face amount of $10,000 which bears interest at an annual rate of 10% (the "Bridge Notes") and warrants to purchase 5,000 shares of Class A Common Stock at $1.25 per share (which was increased in 1998 to 10,000 shares per unit due to our failure to register the Class C Warrants with the Securities and Exchange Commission in a timely manner). The Bridge Notes became due six months from issuance and were repaid in 1998. The Class C Warrant holders have certain rights to require us to register their Page 12 Warrants and underlying shares of Class A Common Stock issuable upon exercise of the Warrants under the Securities Act of 1933, as amended. The Warrants may be redeemed for $0.05 if the Target Price of $4.00 per share (subject to adjustment) for the Company's Class A Common Stock exceeds $4.00 per share for 30 consecutive business days. The number and price of Class A Common Shares subject to the Class C Warrants are subject to adjustment if the underlying shares are recapitalized, otherwise adjusted or if there are subsequent issuances of securities by us. The Warrants expire on December 31, 2002. We sold $540,000 of Bridge Notes from which we received $505,000 in net proceeds. The offering was made pursuant to SEC Regulation D and was limited to accredited investors as defined by Regulation D. Debt issuance costs related to these notes of $35,000, plus the fair value of the Class C warrants issued of $110,700 were netted against the liability and were amortized as additional interest expense over the term of the notes. On September 1, 1998, we sold 175,439 shares of Series A Preferred Stock. All of the shares of Series A Preferred Stock were sold to Anchor Products Limited of Hamilton, New Zealand ("Anchor"). The acquisition of Series A Preferred Stock by Anchor was consummated in connection with the execution of a Commercial License Agreement between us and Anchor, whereby we licensed to Anchor a technology that isolates proteins from whey, a low value cheese by-product. The shares of Series A Preferred Stock were sold for cash in the aggregate amount of $500,000 ($2.85 per share). There were no underwriting discounts or commissions paid in connection with the transaction. The shares of Series A Preferred Stock were sold pursuant to exemptions from registration under section 4(2) and Regulation S under the Securities Act of 1933, in a transaction that was not publicly offered. Anchor is a New Zealand corporation. Our Series A Preferred Stock provides for both a 7.5% dividend and liquidation preferences. The dividend is payable from time to time at the election of the Board of Directors of the Company subject to the Company retaining sufficient earnings and profits. The Preferred Stock is also convertible on or before September 30, 2000 into Class A Common Stock, at the conversion rate of $2.86 per share. On any voluntary or involuntary liquidation, dissolution or winding-up of the Company, the holders of series A Preferred Shares shall receive, out of the assets of the Company, the sum of $2.86 per Series A Preferred Share, plus an amount equal to any dividend accrued and unpaid on those series A Preferred Shares, before any payment shall be made or any assets distributed to the holders of Common Stock. The Series A Preferred Shares shall be redeemable at the option of the holders of the Series A Preferred Shares commencing September 30, 2003 and expiring December 31, 2008, at the cash price of $2.86 per share, plus any accrued and unpaid dividends on the Series A Preferred Shares which are redeemed. In addition, each share of Series A Preferred Stock shall be automatically converted into one (1) share of Class A Common Stock, if not previously redeemed, on January 1, 2009, or at any time the closing bid price per share of our Class A Common Stock shall average at least $3.86 per share over ninety (90) consecutive trading days prior to January 1, 2004. The conversion ratio for the Series A Preferred Stock shall be adjusted in the event of recapitalization, stock dividend, or any similar event affecting the Class A Common Stock. Anchor may require us to immediately redeem the preferred shares in the event of certain covenant breaches of the license agreement by us. We are currently in compliance with all such covenants and do not anticipate any future material breach. On December 15, 1998, we issued to Charles Janac 781,457 shares of Class A Common stock and Warrants to purchase 234,667 shares of Class A Common Stock at $0.46875 per share (expiring August 19, 2003) in exchange for the conversion of $366,308 of notes and accrued interest held by Mr. Janac. The shares of Class A Common Stock and warrants were sold pursuant to exemptions from registration under sections 3(a)(11), 4(2) and 4(6) and Regulation D under the Securities Act of 1933, in a transaction that was not publicly offered. Page 13 On December 15, 1998,we issued to Eliezer Sternheim 520,833 shares of Class A Common stock and Warrants to purchase 52,083 shares of Class A Common Stock at $0.48 per share (expiring December 15, 2003) in exchange for $250,000 cash. The shares of Class A Common Stock and warrants were sold pursuant to exemptions from registration under sections 4(2) and 4(6) under the Securities Act of 1933, in a transaction that was not publicly offered. On December 15, 1998, we issued to Armin Ramel, a director of the Company, 59,946 shares of Class A Common stock and Warrants to purchase 5,995 shares of Class A Common Stock at $0.48 per share (expiring December 15, 2003) in exchange for the conversion of $28,774 of notes and accrued interest held by Mr. Ramel. The shares of Class A Common Stock and warrants were sold pursuant to exemptions from registration under sections 3(a)(11), 4(2) and 4(6) under the Securities Act of 1933, in a transaction that was not publicly offered. On December 15, 1998, we issued to Henry Edmunds, a director of the Company, 127,471 shares of Class A Common stock and Warrants to purchase 12,747 shares of Class A Common Stock at $0.48 per share (expiring December 15, 2003) in exchange for $50,000 cash and the conversion of $11,186 of notes and accrued interest held by Mr. Edmunds. The shares of Class A Common Stock and warrants were sold pursuant to exemptions from registration under sections 3(a)(11), 4(2) and 4(6) under the Securities Act of 1933, in a transaction that was not publicly offered. On December 15, 1998, we issued to Marcel Raedts, an employee of the Company, 104,167 shares of Class A Common stock and Warrants to purchase 10,417 shares of Class A Common Stock at $0.48 per share (expiring December 15, 2003) in exchange for the conversion of $50,000 in amounts owed to Mr. Raedts for services rendered. The shares of Class A Common Stock and warrants were sold pursuant to exemptions from registration under section 4(2) of the Securities Act of 1933, in a transaction that was not publicly offered. On December 15, 1998, we issued to Michael Schneider, former principal and director of Romic Technologies Corp., 275,614 shares of Class A Common stock and Warrants to purchase 27,561 shares of Class A Common Stock at $0.48 per share (expiring December 15, 2003) in exchange for the conversion of $132,294 of notes and accrued interest held by Mr. Schneider. The shares of Class A Common Stock and warrants were sold pursuant to exemptions from registration under sections 3(a)(11), 4(2) and 4(6) under the Securities Act of 1933, in a transaction that was not publicly offered. On December 15, 1998, we issued to Robert Leach, a former director of the Company, 32,475 shares of Class A Common stock and Warrants to purchase 3,248 shares of Class A Common Stock at $0.48 per share (expiring December 15, 2003) in exchange for the conversion of $15,588 of notes and accrued interest held by Mr. Leach. The shares of Class A Common Stock and warrants were sold pursuant to exemptions from registration under sections 3(a)(11), 4(2) and 4(6) under the Securities Act of 1933, in a transaction that was not publicly offered. The Company issued 625,000 of its Class A Common Stock at $0.48 per share, to two individual investors in December, 1998. Net proceeds were $300,000. In addition to the warrants issued to Mr. Janac in connection with the debt financing described in Note 6, the Company has issued an additional warrants to purchase 112,951 shares of Class A Common Stock to other shareholders and creditors who converted outstanding debt into common stock in December, 1998. The warrants were issued on substantially the same terms as those issued to Mr. Janac. In September 1999, Sepragen Corporation sold 290,667 shares of Class A Common Stock at $0.75 per share to four investors in a private transaction exempt from securities registration under the Securities Act of 1933, as amended, and raised $218,000. In December 1999, the Company sold 922,667 shares of Class A Common Stock at $0.75 per share to six investors and raised $692,000 in gross proceeds and $657,499 in net proceeds. It also converted $129,261 of deferred salary and consulting fees into 142,013 Class A Common Stock. These transactions were exempt from securities registration under the Securities Act of 1933, as amended. Page 14 In March 2000, the Company sold 2,022,334 shares of Class A Common Stock at $0.75 per shares to ten investors and raised $1,516,750 in gross proceeds and $1,369,480 in net proceeds. pursuant to a private offering managed by Crown Point. LLC. The shares were offered on a best efforts basis for a selling commission of 5% of gross proceeds and warrants to purchase 8% of the shares sold in the offering at an exercise price of $0.50 per share having an expiration date of March 31, 2005. The shares of Class A Common Stock were sold pursuant to exemption from registration under section 4(2) and 4(6) under the Securities Act of 1933 and Regulation D promulgated under the Securities Act of 1933, in a transaction that was not publicly offered. In March 2000, the Company issued 36,000 Class A Common Stock for $27,000 accrued liability, 199,833 Class A Common Stock for $148,565 for notes payable and accrued interest and 60,000 shares of Class A Common Stock for $45,000 for services and accrued liabilities. 30,000 Class A Common shares were sold for the exercise of warrants at $0.50 per share or $15,000. These transactions were exempt from securities registration under the Securities Act of 1933, as amended. In September 2001, the Company sold 2,990,000 Class A Common Stock at $0.25 per share to seven investors and raised $747,500 in gross proceeds and $703,798 in net proceeds. The Company also received a $50,000 Note receivable from a director of the Company to purchase 200,000 shares of Class A Common Stock at $0,25 per share. The shares were offered pursuant to a private offering managed by Crown Point, LLC on a best efforts basis. The shares of Class A Common Stock were sold pursuant to exemption from registration under section 4(2) and 4(6) under the Securities Act of 1933 and Regulation D promulgated under the Securities Act of 1933, in a transaction that was not publicly. Item 6. Management's Discussion and Analysis or Plan of Operation ------ --------------------------------------------------------- The following table sets forth selected financial information with respect to the Company for each of the years in the five year period ended December 31, 2001 which have been derived from the audited financial statements of the Company included elsewhere herein. The selected financial data set forth below should be read in conjunction with the financial statements of the Company and related notes thereto, included elsewhere herein. Selected Financial Data
Year Ended December 31 ----------------------------------------------------------------------- Statements of Operations 2001 2000 1999 1998 1997 ---- ---- ---- ---- ---- Revenues $ 1,153,953 $ 1,495,697 $ 1,689,832 $ 1,987,086 $ 1,619,623 Net Loss $(1,359,973) $(1,496,327) $ (977,617) $(1,206,340) $(1,648,514) Net Loss Per Share $ (0.14) $ (0.18) $ (0.19) $ (0.41) $ (0.58) ----------- ----------- ----------- ----------- ----------- Weighted average number of 9,496,908 8,099,709 5,017,176 2,935,679 2,856,431 shares outstanding ----------- ----------- ----------- ----------- -----------
Page 15
December 31, ----------------------------------------------------------------------- Balance Sheets 2001 2000 1999 1998 1997 ---- ---- ---- ---- ---- Total Assets $ 895,779 $ 926,853 $ 1,205,518 $ 1,320,089 $ 1,393,036 Total Liabilities $ 1,376,237 $ 789,037 $ 1,293,651 $ 1,537,205 $ 1,898,743 Shareholders' Equity (Deficit) $ (480,458) $ (362,184) $ (700,232) $ (216,707) $ (505,707)
The following table is included as an aid to understanding the Company's operating results. The table sets forth the percentage which each item bears to revenues and the percentage change in dollar amounts from year to year.
Percentage Relationship to Year to Year Percentage Revenues Increase (Decrease) Percent of Percent of Year Year Revenues Revenues Ended Ended Account Name 2001 2000 2001 2000 ------------ ---- ---- ---- ---- Revenues 100% 100% (23)% (11)% Cost and Expenses Cost of goods sold 59% 55% 16% 6% Selling, general and administrative 111% 100% 14% (27)% Research and development 47% 50% 18% (12)% Total costs and expenses 218% 200% 16% (13)% Loss from operations (118)% (100)% 9% (57)% Interest income and other, net (0)% (0)% (0)% (85)% ---- ---- Net loss (118)% (100)% 9% (53)% ==== ==== ====
Results of Operations The management has sought to reposition the Company to sell and service its growing biotech customer base directly. Not withstanding the Company's cash position and the effect of the incidents of September 11, 2001, losses have been reduced and the transition has continued which is expected to result in improved revenues in 2002. Year Ended December 31, 2001 Compared to Year Ended December 31, 2000 Our net loss decreased by $136,000 or 9% from $1,496,000 in 2000 to $1,360,000 in 2001. The decrease was due to lower expenses partially offset by lower sales as described below. In 2001, net sales decreased by $342,000 or 23% from $1,496,000 in 2000 to $1,154,000 in 2001. The operating results of the Company reflect the cash-strapped condition that prevailed for most of the year. The decline in Page 16 shipment was primarily due to cash shortage that hampered our ability to ship orders on hand as well as increase the prospect of future sales. There was no contribution from the dairy sector in 2001. Our gross margin decreased by $208,000 or 31% from $676,000 in 2000 to $468,000 in 2001. As a percentage of sales, gross margin decreased from 45% in 2000 to 41% in 2001. The decrease in gross margin was attributable to the lower volume resulting in higher fixed cost. Selling, general and administrative expense decreased by $216,000 from $1,496,000 in 2000 to $1,280,000 in 2001. The decrease was primarily due to lower sales and marketing expenses such as commission, travel and advertising. Research and development expenses decreased by $126,000 from $673,000 in 2000 to $547,000 in 2001. The decrease in expenses was due to completion of some projects and reduction in research and development activities. For the years ended December 31, 2001 and 2000, sales of our products to foreign markets accounted for approximately 30% and 49%, respectively, of our total sales. Foreign sales expose us to certain risks, including the difficulty and expense of maintaining foreign sales distribution channels, barriers to trade, potential fluctuations in foreign currency exchange rates, political and economic instability, availability of suitable export financing, accounts receivable collections, tariff regulations, foreign taxes, export licensing requirements and other United States and foreign regulations that may apply to the export of our products. In addition, we may experience difficulties in providing prompt and cost-effective service of our products in foreign countries. We do not carry insurance against such risks. The occurrence of any one or more of these events may individually or in the aggregate have a material adverse effect upon our business, operations and financial condition. We attempt to mitigate risks applicable to foreign sales by effecting foreign sales through established independent distributors with greater experience and resources for dealing with foreign customers and foreign trade issues, and by denominating all sales contracts in U.S. dollars, thereby minimizing risks from foreign currency exchange fluctuations. Inflation We believe that the impact of inflation on our operations since our inception has not been material. Volatility of Sales In the last several years, we have experienced a relative increase in customer equipment orders in the third and fourth quarters and a relative decrease in orders in the first and second quarters. We believe this fluctuation relates to capital appropriations and spending cycles in the biopharmaceutical business. Liquidity and Capital Resources We used cash in operations of $746,000 and $1,460,000 during the years ended December 31, 2001 and 2000, respectively. Cash used in operations in 2001 was primarily the result of the net loss incurred for the year of $1,360,000, offset by net depreciation and amortization adjustments to cash of $74,000, and the net increase in operating assets and liabilities of $540,000. Cash used in operations in 2000 was the result of the net loss incurred for the year of $1,496,000 and the net decrease in operating assets and liabilities of $254,000, offset by depreciation and amortization adjustments to cash of $290,000. Investing activities for acquisition of fixed assets used cash of $96,000 and $21,000 for the years ended December 31, 2001 and 2000, respectively. Financing activities provided cash of $837,000 and $1,205,000 during the years ended December 31, 2001 and 2000, respectively. The cash provided in 2001 resulted from the proceeds of issuance of common stock of $704,000 partially offset by the redemption of E shares of $12,000 and proceeds of $145,000 of notes payable. The cash provided in 2000 resulted from the proceeds of issuance of common stock of $1,384,000 partially offset by $179,000 retirements of notes payable. Page 17 At December 31, 2001 we had cash and cash equivalents of $77,000 as compared to $82,000 at December 31, 2000. At December 31, 2001 we had a working capital deficit of $580,000 as compared to working capital of $72,000 at December 31, 2000. The decrease of the working capital by $652,000 from December 31, 2000 to December 31, 2001 is primarily due to the net loss partially offset by the proceeds from common stock and notes payable. Our working capital must increase significantly in order to fund the level of manufacturing and marketing required to meet any growth in demand for our products from the dairy, food and beverage, pharmaceutical and biotechnology industries during the next few years. Moreover, we require additional funds to extend the use of our technology to new applications within the pharmaceutical and biotechnology industries as well as to applications within the food and dairy industries and to attract the interest of strategic partners in one or more of these markets. Since the IPO, we have funded our working capital requirements substantially from sales, net cash proceeds from the IPO and private offerings of securities. Prior to the IPO, we had funded our activities primarily through sales of our Superflo(R) columns and QuantaSep(R) systems, loans from our principal shareholders, and private placements of securities. From our inception, our expenditures have exceeded our revenues. Prior to the IPO, we financed our operations primarily through private equity placements in an aggregate amount of approximately $3,971,000, a substantial portion of which was purchased by H. Michael Schneider, the secretary and a director of the Company until October 1, 1995, and his affiliates, including Romic Environmental Technologies Corporation ("Romic"), an entity that was controlled by Mr. Schneider. In addition, we have historically relied on customers to provide purchase price advances for development and scale-up of our radial flow chromatography columns. See additional capital financing described under Item 5. Our financing requirements may vary materially from those now planned because of changes in the focus and direction of research and development programs, relationships with strategic partners, competitive advances, technological change, changes in our marketing strategy and other factors, many of which will be beyond our control. Based on our current operating plan, we believe that we will be able to fund the Company's operations for the next 6 months. We are currently pursuing several avenues to raise additional capital including increasing revenues and reducing costs, entering into additional strategic partnerships and seeking to secure either debt or equity financing. In August 1998, we announced the signing of a ten years license agreement with Anchor Products. Under this agreement, Anchor Products will have exclusive manufacturing rights to the Sepralac Process in Australia and New Zealand and non-exclusive world wide marketing rights to products produced by the Sepralac process. In return, we received $700,000 out of a total of about $1 million from Anchor Products, comprised of license fees of $200,000 and an equity investment of $500,000 for the purchase of 175,439 redeemable, cumulative, preferred stock at $2.85 per share. The preferred stock is convertible in to Class A Common Stock (on share for share basis) at any time within the next two years and extendible for a further one year at our option. On October 15, 1998, we announced a five-year licensing agreement for the Sepralac process with Carbery Milk products of Ballineen, County Cork, Ireland. Under the agreement, Carbery will have a manufacturing and marketing rights to certain products produced from the Sepralac Process. In return we will receive a license fee of $350,000, $200,000 was received in 1998 with the balance over three years at $50,000 per year. The IPO Units, Class A Common Stock and Class A and Class B warrants were delisted from the NASDAQ SmallCap Market on August 15, 1997 and Pacific Stock Exchange ("PSE") on July 8, 1998. We did not meet the requirements for continued listing of securities on NASDAQ SmallCap Market and Pacific Stock Exchange. Since August 16, 1997, the Class A Common Stock has been trading in the over-the-counter market. As a result, an investor will likely find it more Page 18 difficult to dispose of or to obtain accurate quotations as to the value of our securities. It is also likely that our securities will be less liquid with a resulting negative effect on the value of such securities and our ability to raise additional capital. We currently have no credit facility with a bank or other financial institution. Historically, we and certain of our customers have jointly borne a substantial portion of developmental expenses on projects with such customers through purchase price advances or joint development projects with each party sharing some of the costs of development. There can be no assurance that such sharing of expenses will continue. We will continue our efforts to increase sales of our existing products and to complete development and initiate marketing of our products and processes now under development. We are seeking to enter into strategic alliances with corporate partners in the industries comprising our primary target markets (biopharmaceutical, food and dairy). Our ability to develop and market our Sepralac process for whey separation and other potential food products and processes will be substantially dependent upon our ability to negotiate partnerships, joint ventures or alliances with established companies in each market. In particular, we will be reliant on such joint venture partners or allied companies for market introduction, operational assistance and financial assistance. We believe that development, manufacturing and market introduction of products in these industries will cost millions of dollars and require operational capabilities in excess of those currently available to us. No assurance can be given, however, that the terms of any such alliance will be successfully negotiated or that any such alliance will be successful. We hope to enter into alliances that will provide funding to us for the development of new applications of our Radial Flow Chromatography (RFC) technology in return for agreements to purchase our equipment and royalty bearing licenses to the developed applications. Cautionary Statement for Purposes of the "Safe Harbor" Provisions of the Private Securities Litigation Reform Act of 1995 This report contains or incorporates by reference forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Where any such forward-looking statement includes a statement of the assumptions or bases underlying such forward-looking statement, we caution that, while such assumptions or bases are believed to be reasonable and are made in good faith, assumed facts or bases almost always vary from the actual results, and the differences between assumed facts or bases and actual results can be material, depending upon the circumstances. Where, in any forward-looking statement, our Company or its management expresses an expectation or belief as to future results, such expectation or belief is expressed in good faith and is believed to have a reasonable basis, but there can be no assurance that the statement of expectation or belief will result or be achieved or accomplished. The words "believe," "expect," "estimate," "anticipate," and similar expressions may identify forward-looking statements. Taking into account the foregoing, the following are identified as some but not all of the important factors that could cause actual results to differ materially from those expressed in any forward-looking statement made by us, or on our behalf: Inability to Secure Additional Capital. We have incurred operating losses each fiscal year since our inception. We must restore positive cash flow or secure additional financing through either the sale of additional securities or debt financing to continue operations beyond the next 6 months. Although we are attempting to secure additional financing, there can be no assurance that such financing will be available to us on reasonable terms or at all. We have not met the listing requirements required for continued listing of its securities on the NASDAQ SmallCap Market and the Pacific Exchange Tier II and the Company's stock is thinly traded on the over the counter bulletin board. See Item 6 "Management's Discussion and Analysis or Plan of Operation-Liquidity and Capital Resources." Competition. In both our biopharmaceutical industry market and in the market for its process systems for the food, beverage, and dairy industries, we face intense competition from better-capitalized competitors. See Item 1 "Business-Competition." Page 19 Dependence on Joint Ventures and Strategic Partnerships. Our entry into the food, dairy and beverage market for our process systems will be substantially dependent upon our ability to enter into strategic partnerships, joint ventures or similar collaborative alliance with established companies in each market. There can be no assurance that the terms of any such alliances will produce profits. See Item 1 "Business-Necessity of Alliances and Partnerships." Dependence on key personnel: Our success will depend, in large part, on our ability to attract and retain highly qualified scientific and business personnel, competition for which is intense. We may be unable to retain the necessary personnel to implement our business plan. Dependence on key vendors: We depend on key vendors to supply us with key components for our products. Any disruptions at these vendors or their ability to supply products or services could adversely affect our ability to deliver on our commitments to our customers. Item 7. Financial Statements ------ -------------------- (a) Financial Statements. The financial statements of the Company as of December 31, 2001, and for the year then ended have been audited by Bedinger & Company, independent accountants, as indicated in their report thereon. The financial statements included in this section are as follows: Page ---- Report of Independent Certified Public Accountants, Bedinger & Company ..... 21 Balance Sheet as of December 31, 2001 ...................................... 22 Statements of Operations for the years ended December 31, 2001 and 2000 .... 23 Statement of Shareholders' Equity (Deficit) for the years ended December 31, 2001 and 2000 ................................................. 24 Statements of Cash Flows for the years ended December 31, 2001 and 2000 .... 25 Notes to Financial Statements .............................................. 26 Page 20 Independent Auditor's Report February 22, 2002 To the Board of Directors and Shareholders Sepragen Corporation: We have audited the accompanying balance sheet of Sepragen Corporation (the "Company") as of December 31, 2001, and the related statements of operations, shareholders' deficit, and cash flows for each of the two years in the period ended December 31, 2001. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with generally accepted auditing standards. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. In our opinion, the December 31, 2001 financial statements referred to above present fairly, in all material respects, the financial position of Sepragen Corporation as of December 31, 2001, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2001 in conformity with generally accepted accounting principles. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. However, the Company has suffered recurring losses from operations that raises substantial doubt about its ability to continue as a going concern. Management plans in regards to these matters are also described in Note B. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Certified Public accountants Bedinger & Company Walnut Creek, California Page 21
SEPRAGEN CORPORATION BALANCE SHEET December 31, 2001 ASSETS Current assets: Cash and cash equivalents $ 76,922 Accounts receivable, less allowance for doubtful accounts of $45,000 416,546 Stock purchase receivable 50,000 Inventories (Note C) 234,258 Prepaid expenses 18,000 ------------ Total current assets 795,726 ------------ Furniture and equipment, net (Note D) 84,094 Intangible Assets, net (Note A) 15,959 ------------ Total assets $ 895,779 ============ LIABILITIES AND DEFICIT IN SHAREHOLDERS' DEFICIT Current liabilities: Trade accounts payable $ 512,787 Notes payable to shareholders (Note E) 215,000 Accrued payroll and benefits 439,740 Accrued liabilities 68,377 Interest payable 39,012 Customer deposit 101,322 ------------ Total current liabilities 1,376,238 ------------ COMMITMENTS (Note K) Redeemable convertible Series A Preferred stock, no par value--5,000,000 shares authorized; 175,439 shares issued and outstanding (total liquidation preference of $500,000) $ 500,000 SHAREHOLDERS' EQUITY (DEFICIT): (Note B) Class A common stock, no par value--20,000,000 shares authorized; 10,972,398 shares issued and outstanding at December 31, 2001 13,524,281 Class B common stock, no par value--2,600,000 shares authorized; 701,177 shares issued and outstanding at December 31, 2001 4,065,618 Accumulated deficit (18,570,358) ------------ Total shareholders' deficit (980,459) ------------ Total liabilities and shareholders' deficit $ 895,779 ============
The accompanying notes are an integral part of this financial statement. Page 22 SEPRAGEN CORPORATION STATEMENTS OF OPERATIONS For the Year Ended December 31, --------------------------- 2001 2000 ---- ---- Revenues: Net sales $ 1,153,953 $ 1,495,697 Cost of goods sold 686,386 819,757 ----------- ----------- Gross margin 467,567 675,940 Selling, general, and administrative 1,280,259 1,495,752 Research and development 547,282 672,808 ----------- ----------- Total costs and expenses 2,513,927 2,988,317 ----------- ----------- Loss from operations (1,359,974) (1,492,620) Interest expense 0 (3,707) Net loss (1,359,974) (1,496,327) ----------- ----------- Loss per common share, basic and diluted $ (0.14) $ (0.18) Weighted average common shares outstanding 9,496,908 8,099,719 The accompanying notes are an integral part of these financial statements. Page 23
SEPRAGEN CORPORATION STATEMENTS OF SHAREHOLDERS' DEFICIT FOR THE YEARS ENDED DECEMBER 31, 2000 AND 1999 ------------------------------------------------------------------------------------------------------------------------------------ Common Stock ------------------------------------------------------- Class A Class B ------- ------- Additional Total Number of Number of Paid-in Accumulated Shareholder's Shares Amount Shares Amount Capital Deficit Deficit ------------ ------------ ------------ ------------ ------------ ------------ ------------ BALANCES December 31, 1999 5,412,562 10,948,207 701,177 4,065,618 -- (15,714,057) (700,232) Conversion of Series A Preferred Stock 35,002 100,000 100,000 Issuance of Class A Common Stock at $0.68 per share (net of offering costs of $5,707) 2,022,334 1,369,480 1,369,480 Issuance of Class A Common Stock for accrued liabilities at $0.75 per share 36,000 27,000 27,000 Issuance of Class A Common Stock for notes payable and accrued interest at $0.74 per share 199,833 148,565 148,565 Compensation for issuance of stock options 129,330 129,330 Exercise of Warrants to purchase Class A Common Stock at $0.50 per share 30,000 15,000 15,000 Issuance of Class A Common Stock for services and accrued liabilities at $0.75 per share 60,000 45,000 45,000 Net loss for period ending 12/31/01 (1,496,327) (1,496,327) ------------ ------------ ------------ ------------ ------------ ------------ ------------ BALANCES December 31, 2000 7,795,731 $ 12,782,582 701,177 $ 4,065,618 $ -- $(17,210,384) $ (362,184) ============ ============ ============ ============ ============ ============ ============ Issuance of Class A Common Stock at $0.25 per share (net of offering costs of $43,702) 2,990,000 703,798 703,798 Issuance of Class A Common Stock in exchange of a note receivable 200,000 50,000 50,000 Redemption of Class E Common ` (12,099) (12,099) Cancellation of Class A Common (13,333) Net loss for period ending 12/31/01 (1,359,974) (1,359,974) BALANCES December 31, 2001 10,972,398 $ 13,524,281 701,177 $ 4,065,618 $ -- $(18,570,358) $ (980,459) ============ ============ ============ ============ ============ ============ ============
See Notes to Financial Statements Page 24
SEPRAGEN CORPORATION STATEMENT OF CASH FLOWS ------------------------------------------------------------------------------------------------------------ Year Ended December 31, -------------------------- 2001 2000 ----------- ----------- CASH FLOWS FROM OPERATING ACTIVITIES Net loss ($1,359,974) ($1,496,327) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation 44,489 90,944 Amortization 29,272 24,978 Issuance of common stock at a discount 174,330 CHANGES IN CURRENT ASSETS AND CURRENT LIABILITIES (Increase) Decrease in current assets: Accounts receivable 36,072 (53,601) Inventories 31,121 (4,843) Prepaid expenses 30,486 (33,975) Increase (Decrease) in current liabilities: Accounts payable 75,231 (92,852) Accrued liabilities (23,493) (38,482) Accrued payroll and benefits 315,253 (28,194) Interest payable (306) (27,991) Customer deposits 75,516 25,806 ----------- ----------- NET CASH USED FOR OPERATING ACTIVITIES: (746,333) (1,460,207) ----------- ----------- CASH FLOWS FROM INVESTING ACTIVITIES: Acquisition of fixed assets (95,610) (20,905) ----------- ----------- NET CASH (USED) FOR INVESTING ACTIVITIES (95,610) (20,905) ----------- ----------- CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from issuance of common stock 703,798 1,369,480 Redemption of Common E shares (12,099) Proceeds from exercise of warrants 15,000 Net proceeds (principal repayments) from notes payable from stockholders' 170,000 (134,435) Net repayments of notes payable (25,000) (45,000) ----------- ----------- NET CASH (USED) PROVIDED BY FINANCING ACTIVITIES 836,699 1,205,045 ----------- ----------- NET INCREASE (DECREASE) IN CASH (5,244) (276,067) CASH, beginning of period 82,166 358,233 ----------- ----------- CASH, end of period $ 76,922 $ 82,166 =========== =========== SUPPLEMENTAL DISCLOSURE Cash paid during the year for $ 800 $ 800 taxes Conversion of liabilities into common stock 175,565 Cash paid for interest 18,000 Conversion (Redemption) of Class E to (12,099) 12,099 liability
See Notes to Financial Statements Page 25 SEPRAGEN CORPORATION NOTES TO FINANCIAL STATEMENTS Years ended December 31, 2001 and 2000 Note A - Operations and Summary of Significant Accounting Policies: Operations: Sepragen Corporation (the "Company") develops, manufactures and markets proprietary liquid chromatography columns and computer-controlled liquid chromatography process systems. These products are used by the biopharmaceutical industry for the separation and purification of a broad range of molecules. Summary of Significant Accounting Policies: Use of Estimates: The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Concentrations of Credit Risk: The Company performs ongoing credit evaluations of its customers. The Company maintains reserves for potential credit losses on customer accounts, when probable, and such losses have been within management's expectations. Approximately 30% and 49% of net sales for the years ended December 31, 2001 and 2000, respectively, were to customers outside the United States. For the year ended December 31,2001, two customers individually accounted for 34% and 13% of sales. For the year ended December 31, 2000, the Company had two customers who individually accounted for 20% and 15% of sales. For the year ended December 31, 2001, three customers individually accounted for 35%, 14% and 9% of accounts receivable. Cash and Cash Equivalents: The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Inventories: Inventories are stated at the lower of cost, using the first-in, first-out method, or market. Management performs periodic assessments to determine the existence of obsolete, slow moving and non-salable inventories, and records necessary provisions to reduce such inventories to net realizable value. Furniture and Equipment: Furniture and equipment are stated at cost. Depreciation of furniture and equipment is computed using the straight-line method over the estimated useful lives of the assets that range from two to five years. Maintenance and repairs are charged to expense as incurred while major improvements are capitalized. Leasehold improvements are amortized over their useful lives or lease term, whichever is shorter. Intangible Assets: Intangible assets, consisting of internal and purchased patent application costs, are recorded at cost. These assets are being amortized on the straight-line basis over the estimated useful lives of the patents of approximately seven years. Accumulated amortization on patents is $174,060 on December 31, 2001. Page 26 SEPRAGEN CORPORATION NOTES TO FINANCIAL STATEMENTS Years ended December 31, 2001 and 2000 Fair value of financial instruments. The fair value of cash and cash equivalents, accounts receivable and accounts payable approximates carrying value due to the short-term nature of such instruments. Based on borrowing rates currently available to the Company for bank loans with similar terms and maturities, the fair value of the Company's notes payable approximates the carrying value. Income Taxes: The Company uses an asset and liability approach for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period plus or minus the change in deferred tax assets and liabilities during the period. Revenue Recognition: The Company recognizes revenue from product sales upon shipment and customer acceptance. Research and development: Expenses related to present and future products are expensed as incurred. Loss Per Common Share: Basic loss per share is calculated using the weighted average number of common shares outstanding in the period. Diluted loss per share includes potentially dilutive securities such as outstanding options and warrants, using the "treasury stock "method and convertible securities using the "if-converted" method. The assumed exercise of options and warrants and assumed conversion of convertible securities have not been included in the calculation of diluted loss per share as the affect would be anti-dilutive. Stock Based Compensation: Compensation expense is recorded when the exercise price of options is less than the fair value of the common stock at the measurement date, or when options previously issued are modified. Impact of Accounting Standards: In June 2001, the FASB issued SFAS No. 141, "Business Combinations" and SFAS No. 142 "Goodwill and Other Intangible Assets." Under these new standards, all acquisitions subsequent to June 30, 2001 must be accounted for under the purchase method of accounting and purchased goodwill is no longer amortized over its useful life. Instead, goodwill will be subject to a periodic impairment test based upon its value. The Company does not expect any effect on its financial position or results of operations from the adoption of this statement. In August 2001, the FASB issued SFAS No. 143, "Accounting for Asset retirement Obligations." SFAS 143 establishes accounting standards for recognition and measurement of a liability for the costs of asset retirement obligations. Under SFAS 143, the costs of retiring an asset will be recorded as a liability when the retirement obligation arises, and will be amortized to expense over the life of the asset. The Company does not expect any effect on its financial position or results of operations from the adoption of this statement. In October 2001, the FASB issued SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets." SFAS 144 addresses financial accounting and reporting for the impairment or disposal of long lived assets and discontinued operations. The Company does not expect any effect on its financial position or results of operations from the adoption of this statement. Note B - Going Concern and management plans: The Company will be required to conduct significant research, development and testing activities which, together with expenses to be incurred for manufacturing, the establishment of a large marketing and distribution presence and other general and administrative expenses, are expected to result in operating losses for the next few quarters. Accordingly, there can be no assurance that the Company will continue as a going concern. The Company has incurred recurring losses and cash flow deficiencies from operations that raise substantial doubt about its ability to continue as a going concern. The Company's continued existence is dependent upon its ability to increase Page 27 SEPRAGEN CORPORATION NOTES TO FINANCIAL STATEMENTS Years ended December 31, 2001 and 2000 operating revenues and/or raise additional equity capital sufficient to generate enough cash flow to finance operations in future periods. Management is currently in the process of seeking additional equity financing with potential investors. There can be no assurance that such additional financing will be obtained. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Note C - Inventories: Inventories consist of the following at December 31, 2001: Raw materials $ 103,565 Work in process 46,707 Finished goods 83,986 --------- $ 234,258 ========= Note D - Furniture and Equipment: Furniture and equipment consist of the following at December 31, 2000: Leasehold improvement $ 91,968 Office equipment 94,642 Machinery 93,831 Furniture and fixtures 5,813 Lab Equipment 114,033 Autos 6,309 --------- 406,596 Less accumulated depreciation and amortization (322,502) --------- $ 84,094 ========= Note E - Notes Payable: Between May 1997 and August 1998, the Company borrowed an aggregate of $400,000 payable with interest at 9.5% per annum, of which $300,000 was from shareholders of the Company and $100,000 was from an unrelated party. In December 1998, the Company converted $165,000 of the shareholder's debt including accrued interest of $11,657 into 368,035 shares of Class A Common Stock. In 1999, the Company paid $20,000 to a shareholder. In August, 1999, the Company received proceeds from a convertible note payable from a shareholder of $260,000 with interest at 9.5% per annum. In March 2000, a shareholder converted $130,000 Note payable into 173,333 shares of Class A Common stock. The remaining balance of $130,000 was paid in April 2000. Between January and March 2000, the Company repaid $30,000 of the shareholder notes and converted $10,000 of related party notes payable accrued interest into 11,150 shares of Class A Common Stock. In 2000, the Company paid $25,000 to unrelated party and $25,565 to shareholders. In December 2000, the Company received $50,000 in convertible notes payable with interest at 10% per annum from a shareholder. Between February and November 2001, the Company borrowed an aggregate of $170,000 in convertible notes payable with interest at 7% per annum from various shareholders. The company repaid $25,000 of these notes payable during the year. Page 28 SEPRAGEN CORPORATION NOTES TO FINANCIAL STATEMENTS Years ended December 31, 2001 and 2000 NOTE F - Series A Preferred Stock On September 1, 1998, the Company sold 175,439 shares of Series A Preferred Stock to Anchor Products Limited of Hamilton, New Zealand ("Anchor"). The acquisition of Series A Preferred Stock by Anchor was consummated in connection with the execution of a Commercial License Agreement between the Company and Anchor, whereby the Company licensed Anchor a technology that isolates proteins from whey, a low value cheese by-product. The shares of Series A Preferred Stock were sold for cash in the aggregate amount of $500,000 ($2.85 per share). There were no underwriting discounts or commissions paid in connection with the transaction. The shares of Series A Preferred Stock were sold pursuant to exemptions from registration under section 4(2) and Regulation S under the Securities Act of 1933, in a transaction that was not publicly offered. Anchor is a New Zealand corporation. The Company's Series A Preferred Stock provides for both a 7.5% dividend and liquidation preferences. The dividend is payable from time to time at the election of the Board of Directors of the Company subject to the Company retaining sufficient earnings and profits. On any voluntary or involuntary liquidation, dissolution or winding-up of the Company, the holders of series A Preferred Shares shall receive, out of the assets of the Company, the sum of $2.86 per Series A Preferred Share, plus an amount equal to any dividend accrued and unpaid on those series A Preferred Shares, before any payment shall be made or any assets distributed to the holders of Common Stock. The Series A Preferred Shares shall be redeemable at the option of the holders of the Series A Preferred Shares commencing September 30, 2003 and expiring December 31, 2008, at the cash price of $2.86 per share, plus any accrued and unpaid dividends on the Series A Preferred Shares, which are redeemed. In addition, each share of Series A Preferred Stock shall be automatically converted into one (1) share of Class A Common Stock, if not previously redeemed, on January 1, 2009, or at any time the closing bid price per share of the Company's Class A Common Stock shall average at least $3.86 per share over ninety (90) consecutive trading days prior to January 1, 2004. The conversion ratio for the Series A Preferred Stock shall be adjusted in the event of recapitalization, stock dividend, or any similar event affecting the Class A Common Stock. Anchor may require the Company to immediately redeem the preferred shares in the event of certain covenant breaches of the license agreement by the Company. The Company is currently in compliance with all such covenants and does not anticipate any future material breach. On September 15, 1999, the Company issued 35,002 shares of Series A Preferred Stock to Monterey Mechanical Co. of Oakland, California upon the conversion of $100,000 of accounts payable into Series A Preferred Stock at $2.86 per share. The terms and conditions of the Preferred Stock held by Monterey Mechanical are the same as those for Anchor Products. On March 17, 2000, Monterey Mechanical converted all of its 35,002 shares of Series A Preferred Stock into 35,002 shares of Class A Common Stock. Note G - Class A Common Stock The Company issued 625,000 of its Class A Common Stock at $.48 per share, to two individual investors in December, 1998. Net proceeds were $300,000. In addition to the warrants issued to a shareholder in connection with the debt financing, the Company has issued an additional warrants to purchase 112,951 shares of Class A Common Stock to other shareholders and creditors who converted outstanding debt into common stock in December, 1998. The warrants were issued on substantially the same terms as those issued to a shareholder. In September 1999, Sepragen Corporation sold 290,667 shares of Class A Common Stock at $.75 per share to four investors in a private transaction exempt from securities registration under the Securities Act of 1933, as amended, and raised $218,000.In December 1999, the Company sold 922,667 shares of Class A Common Stock at $.75 per share to six investors and raised $692,000 in gross proceeds and $657,499 in net proceeds. It also converted $129,261 of deferred salary and consulting fees into 142,013 Class A Common Stock. These transactions were exempt from securities registration under the Securities Act of 1933, as amended. In March 2000, the Company sold 2,022,334 shares of Class A Common Stock at $.75 per shares to ten investors and raised $1,516,750 in gross proceeds and $1,369,480 in net proceeds, pursuant to a private offering managed by Crown Point. LLC. The shares were offered on a best efforts basis for a selling commission of 5% of gross proceeds and warrants to purchase 8% of the Page 29 SEPRAGEN CORPORATION NOTES TO FINANCIAL STATEMENTS Years ended December 31, 2001 and 2000 shares sold in the offering at an exercise price of $0.50 per share having an expiration date of December 31, 2002. The shares of Class A Common Stock were sold pursuant to exemption from registration under section 4(2) and 4(6) under the Securities Act of 1933 and Regulation D promulgated under the Securities Act of 1933, in a transaction that was not publicly offered. In March 2000, the Company issued 36,000 Class A Common Stock for $27,000 accrued liability, 199,833 Class A Common Stock for $148,565 for notes payable and accrued interest and 60,000 shares of Class A Common Stock for $45,000 for services and accrued liabilities. 30,000 Class A Common shares were sold for the exercise of warrants at $0.50 per share or $15,000. These transactions were exempt from securities registration under the Securities Act of 1933, as amended. In September 2001, the Company sold 2,990,000 shares of Class A Common at $0.25 per share to seventeen investors and raised $747,500 in gross proceeds and $703,398 in net proceeds. The Company also received a $50,000 note receivable from a director to purchase 200,000 shares of Class A Common at $0.25 per share. These transactions were exempt from securities registration under the Securities Act of 1933, as amended. During 2001, the Company issued warrants to shareholders to purchase 670,200 shares of the Company's Class A Common Stock. The vesting period of these warrants range from immediate to two years, with expiration dates ranging from three to five years. The exercise price of these warrants is $0.25. The company also cancelled 13,333 shares of Class A Common Stock that were previously issued for no consideration. The company redeemed the Class E Common Stock in the amount of $12,099. Note H - Stock Options The Company has issued non-qualified stock options to purchase shares of the Company's common stock to certain employees, consultants, and directors. The options vest over a period of one to ten years. Shares issued under the existing stock option agreements are subject to various restrictions as to resale and right of repurchase by the Company. Generally, the exercise price is not less than the fair value of the common stock at the date of grant. In August 1994 and June 1996, the Board of Directors of the Company adopted the 1994 and 1996 Sepragen Corporation Stock Option Plans (the "Stock Option Plans"). The Stock Option Plans provide for the issuance of options covering up to 400,000 and 250,000 shares of Class A common stock (subject to adjustments in the event of stock splits, stock dividends and similar dilutive events), respectively. Options may be granted under the Stock Option Plans to employees, officers or directors of, and consultants and advisors to, the Company. Options will be granted under the Stock Option Plans within the sole discretion of the Board of Directors. Options granted to employees may either be incentive stock options (as defined in the Internal Revenue Code of 1986, as amended) or nonqualified stock options. The purchase price of Class A common stock subject to an option shall be determined by the Board of Directors at the time of grant, provided that the purchase price of incentive stock options is not less than the fair market value of the Company's Class A common stock on the date of grant. Subject to the foregoing, the terms of each option and the increments in which it is exercisable are determined by the Board of Directors, provided that no option may be exercised before one year or after ten years from the date of grant. To the extent that the aggregate fair market value, as of the date of grant, of the shares for which incentive stock options become exercisable for the first time by an optionee during any calendar year exceeds $100,000, the portion of such option which is in excess of the $100,000 limitation will be treated as a nonqualified stock option. In addition, if an optionee owns more than 10% of the total voting power of all classes of the Company's stock at the time the individual is granted an incentive stock option, the purchase price per share cannot be less than 110% of the fair market value on the date of grant and the term of the incentive stock option cannot exceed five years from the date of grant. Page 30 SEPRAGEN CORPORATION NOTES TO FINANCIAL STATEMENTS Years ended December 31, 2001and 2000 The Company has 218,324 options that are outstanding that are held by the CEO at exercise prices ranging from $0.38 to $5.00. These options have vested based upon prior performance objectives. The following table summarizes the Company's stock option activity for the years ended December 31: 2001 2000 ----------------------- ----------------------- Weighted- Weighted- Average Average Exercise Exercise Shares Price Shares Price ---------- ---------- ---------- ---------- Outstanding at beginning of year 1,468,361 $ 1.23 1,298,361 $ 1.29 Granted 54,000 0.50 170,000 0.83 Forfeited (725,058) 0.69 -- -- ---------- ---------- ---------- ---------- Outstanding at end of year 797,303 1.68 1,468,361 $ 1.23 ========== ========== ========== ========== Options exercisable at 616,428 1,201,361 year-end ========== ========== Page 31 SEPRAGEN CORPORATION NOTES TO FINANCIAL STATEMENTS Years ended December 31, 2001 and 2000 The following table summarizes information about the Company's stock options outstanding at December 31, 2001:
Options Outstanding Options Exercisable ----------------------------------------- -------------------------- Number Average Weighted Number Range of Outstanding Remaining Average Outstanding at Weighted Exercise at December Contractual Exercise December 31, Average Prices 31, 2001 Life (years) Price 2001 Exercise Price -------- ----------- ----------- ----------- ----------- ----------- $0.38 to $0.56 196,982 1.74 $ 0.45 186,982 $ 0.45 $0.72 to $1.50 419,000 2.18 0.83 248,125 0.84 $5.00 181,321 3.23 5.00 181,321 5.00 ----------- ----------- ----------- ----------- ----------- Total 797,303 2.31 $ 1.68 616,428 $ 1.95 =========== =========== =========== =========== ===========
In October, 1998, the Company reduced the exercise price of Stock options from $0.88 to $7.62 per share to the fair market value of $0.38 per share for specific individuals. Compensation expense relating to the reduction in exercise price was immaterial to the financial statements. The Company applies APB Opinion 25, "Accounting for Stock Issued to Employees", and related interpretations in accounting for its options issued to employees. The following information is provided in accordance with SFAS No. 123, "Accounting for Stock-Based Compensation." If the compensation cost for these plans had been determined based on the fair value at the grant dates for awards consistent with the method of SFAS Statement 123, the pro forma effect on the Company's net loss per share in 2001 and 2000 would have been: 2001 2000 ---- ---- Net loss as reported $(1,359,974) $(1,496,327) Pro forma $ (1382,114) $(1,620,082) Net loss per share, as reported $ (0.14) $ (0.18) Pro forma $ (0.15) $ (0.20) Page 32 SEPRAGEN CORPORATION NOTES TO FINANCIAL STATEMENTS Years ended December 31, 2001 and 2000 The weighted average fair value of options granted during 2001 and 2000 was $0.41 and $0.79, respectively. The fair value of each option granted in 2001 and 2000 was estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions: 2001 2000 ---- ---- Risk free interest rate 4.64% 5.11% Expected life (years) 4. 4.76 Volatility 175% 179% Dividend yield -- -- Note I - Income taxes Deferred tax assets are comprised of the following at December 31, 2001 (rounded): Net operating loss carry forwards $ 6,456,000 Research and development credit carry forwards 628,000 Other differences between financial reporting and tax basis of assets and liabilities 64,000 =========== 7,148,000 Valuation allowance (7,148,000) ----------- Net deferred tax assets $ -- ----------- Due to the uncertainty of the realization of the net deferred tax assets, the balance has been fully reserved. The valuation allowance increased by $426,000 for the year ended December 31, 2001. The difference between the income tax benefit at the Federal statutory rate and the Company's effective tax rate is as follows: For the years ended December 31: 2001 2000 ---- ---- Risk free interest rate 4.64% 5.11% Statutory federal income tax rate 34% 34% State income taxes 6 6 Change in valuation allowance (40)% (40)% -- -- ===== ===== At December 31, 2001, the Company had net operating loss carry forwards available to reduce its future taxable income of approximately $17,648,000, for federal income tax purposes, and $3,345,000 for California State franchise purposes. These net operating losses expire at various times through 2021. Page 33 SEPRAGEN CORPORATION NOTES TO FINANCIAL STATEMENTS Years ended December 31, 2001 and 2000 (Continued) For federal and state tax purposes, the Company's net operating loss and tax credit carry forwards could be subject to certain limitations on annual utilization due to changes in ownership, as defined by federal and state laws. Note J - Commitments The Company currently rents its office and production facility under an annual operating lease which expires December 31, 2005. Rental expense for the years ended December 31, 2001 and 2000 was $193,004 and $102,120, respectively. The minimum rental commitment remaining on the leased property is as follows: Years Ending December 31: 2002 197,570 2003 204,123 2004 210,937 2005 218,025 -------- Total $830,655 ======== Note K - Segment reporting Sepragen has two operating segments based on the nature of the customer's industry, the biotech and food (dairy) and beverage segments. The chief operating decision-maker is the Company's Chief Executive Officer who regularly reviews segment performance. Selling, general and administrative expenses are not allocated to individual segments. There are no significant assets that are identifiable to a segment. Operating results by segment for the years ended December 31, 2001 and 2000 are as follows: 2001 2000 ---- ---- Food and Food and Biotech Beverage Biotech Beverage ---------- ---------- ---------- ---------- Sales 1,153,953 $ 0 $1,353,000 $ 143,000 Cost of goods 686,306 0 770,000 50,000 ---------- ---------- ---------- ---------- Gross Profit $ 467,567 $ 0 583,000 93,000 Page 34 Item 8. Changes in and Disagreements with Accountants on Accounting and ------ --------------------------------------------------------------- Financial Disclosure. -------------------- (i) Effective January 13, 1998, Coopers & Lybrand, LLP, was dismissed as independent accountants for Sepragen Corporation. (ii) Commencing with the audit report and the financial statements for the Company's fiscal year ended December 31, 1996, Coopers & Lybrand LLP's opinion on the financial condition of the Company was modified due to recurring losses and cash flow deficiencies from operations that raised substantial doubt as to the Company's ability to continue as a going concern, as more fully described in Note 1 to the Company's financial statements for such period. (iii) The decision to change the Company's independent accountants was approved by the Board of Directors of the Company. (iv) There have been and are no current disagreements with Coopers & Lybrand LLP (predecessor entity to Pricewaterhouse Coopers LLP) on any matter of accounting principles or practices, financial statements disclosure, or auditing scope or procedure. (v) Effective February 6, 1998, Grant Thornton LLP, was engaged as principal independent accountant for Sepragen Corporation. (vi) Effective November 28, 2000, Grant Thornton, LLP resigned as principal independent accountants for Sepragen Corporation (vii) There has been no disagreement with Grant Thornton, LLP on any matter of accounting principles or practices, financial statement disclosures, or auditing scope or procedure. (viii) The opinion for the year ended December 31, 1998 was unqualified except for a modification with respect to the Company's ability to continue as a going concern and the opinion for the year ended December 31, 1999 was unqualified. (ix) Effective December 18, 2000, the Company has selected Bedinger Company as its independent accountants. (x) The change of independent accountants was approved by the Board of Directors of the Company. Page 35 PART III -------- Item 9. Directors, Executive Officers, Promoters and Control Persons; ------ ------------------------------------------------------------- Compliance with Section 16(a) of the Exchange Act ------------------------------------------------- The Company's Officers and Directors are elected annually to serve until the next annual meeting of shareholders and thereafter until their successors are elected. The number of Directors presently authorized by the Bylaws of the Company is up to six.
----------------------------------------------------------------------------------------------------- Name, Offices and Position First with the Company or Principal Became a Occupation and Directorships Age Director ---------------------------- --- -------- ----------------------------------------------------------------------------------------------------- VINIT SAXENA 46 1985 President, Chief Executive Officer, Chief Financial Officer, Chairman of the Board and Director of the Company since 1985. He is the inventor of the Company's original radial flow chromatography technology. His background includes several years as a biochemical engineer, product marketing manager, and prior to joining Sepragen, as a product marketing manager for industrial chromatography with Bio-Rad Laboratories (from 1980-1984) and a manager of production and bioengineering for Bio-Response (now Baxter Healthcare) (from 1984-1985). Mr. Saxena has an M.S. in Chemical Engineering from Syracuse University and an M.B.A. from the University of California at Berkeley. Mr. Saxena also serves as a director of Scan Incorporated of Mountain View, California, a privately held artificial intelligence medical imaging company. ----------------------------------------------------------------------------------------------------- ARMIN RAMEL 76 1986 Director of the Company since September 1986 and was elected as Secretary of the Company in 1995. He has been employed since July 1993 as Vice President of Product Development of Scios Nova Inc., a publicly held biotech company. From November 1982 to June 1993, Dr Ramel was employed by Genentech, his last position there being Senior Director of the Process Science Division from April 1991 to June 1993. From 1969 to October 1982, Dr. Ramel was employed in various positions at Hoffmann - La Roche, Inc., his last position there being Director of the Biopolymer Research Department from 1977, to October 1982. Prior to 1969, he was a professor at the University of Basel, Switzerland and State University of New York at Buffalo. Dr. Ramel holds a Ph.D. in physical chemistry from the University of Basel. ----------------------------------------------------------------------------------------------------- HENRY N. EDMUNDS.* 59 1997 Dr. Edmunds became Chief Financial officer of the Company in December 2000. He served as Vice President and Chief Financial Officer of Prometheus, in San Diego, from 1999 to 2000 and was Vice President and Chief Financial Officer of SangStat Medical Corporation, a Menlo Park, California based company, from 1992 to 1999. From 1985 until 1992, Dr. Edmunds was Director of Business Development and business manager of Genencor, Inc., a South San Francisco, California biotechnology company. Dr. Edmunds received his Ph.D. in Biotechnology from the University of California, Berkeley and his M.B.A. from the Stanford University. -----------------------------------------------------------------------------------------------------
Page 36
----------------------------------------------------------------------------------------------------- Name, Offices and Position First with the Company or Principal Became a Occupation and Directorships Age Director ---------------------------- --- -------- ----------------------------------------------------------------------------------------------------- JOHN WALKER.* 55 1998 Mr. Walker successfully managed and sold companies in separations and dairy fields. He founded the Northern California region of TEC (The Executive Committee, an organization dedicated to the empowerment of CEOs). He mentors six new chairpersons of TEC. He also runs his consulting firm John Walker and Associates, which provides, among other things, strategic planning and management assistance to high tech companies. Mr. Walker has a B.A. in Industrial Engineering from Georgia Tech and an M.B.A. from Stanford University. ----------------------------------------------------------------------------------------------------- JOSEPH R. MALLON, JR. 56 1999 On April 1, 1995, Mr. Mallon was appointed President, Chief Executive Officer of the Board of Measurement Specialties, Inc. ("MSI"). Mr. Mallon has served on the Board of Directors of MSI since April 1, 1992. In October 1985, Mr. Mallon co-founded NovaSensor, a leader in the field of micromachined pressure and acceleration sensors, where he served as Co-President and Director until its acquisition in 1990, by Lucas Industries, Inc., a United States subsidiary of Lucas Industries plc of the United Kingdom. From that time until his departure in January of 1993, Mr. Mallon was the Executive Vice President and Director of Lucas Nova Sensor. Mr. Mallon holds a B.S. in Science from Farleigh Dickinson University, and a M.B.A. from California State University. ----------------------------------------------------------------------------------------------------- K.CHARLES JANAC 44 2000 Mr. Janac has served as the President and Chief Executive Officer of Smart Machines, Inc. from November 1994 to September 1999 (when Smart machines was acquired by Brooks Automation), and as Vice President and General Manager of Brooks Automation from October 1999 to present. He has an M.B.A. from Stanford University and MS in Organic Chemistry from Tufts University. Mr. Janac resigned as a director of the Company effective March 1, 2002 ----------------------------------------------------------------------------------------------------- JON A. SALQUIST 56 2001 Mr. Salquist is the managing partner of Mackenzie River Partners. He also serves on the board of D&J research, OMLC (Oregon Medical Laser Center. He is also a partner in Ardent Research a high-tech hedge fund. Mr. Salquist has started several high tech companies and provided financing and direction for numerous others over the last 25 years. Mr. Salquist attended University of Oregon, Portland State University and Stanford Business School for executives (A.E.A). -----------------------------------------------------------------------------------------------------
--------------- * Member of the Compensation Committee and Audit Committee. All directors hold office until the next annual meeting of shareholders and the election and qualification of their successors. Directors receive compensation for serving on the Board of Directors as described below. The Company has established audit and compensation committees, a majority of whose Page 37 members must be non-employee directors. Dr. Edmunds and Mr. Walker serve on the audit and compensation committees. Officers are elected annually by the Board of Directors and serve at the discretion of the Board. Subsequent event: Mr. K. Charles Janac resigned his position as a director of the Company effective March 1, 2002. Indemnification Pursuant to the Company's Articles of Incorporation, as amended, Bylaws and certain written agreements dated October 27, 1994, officers and directors of the Company will be indemnified by the Company to the fullest extent allowed under California law for claims brought against them in their capacities as officers or directors. The Company has obtained directors' and officers' liability insurance. No assurance can be given that the Company will be able to maintain such insurance at a reasonable price. Indemnification will not be provided if the officer or director does not act in good faith and in a manner reasonably believed to be in the best interests of the Company, or, with respect to any criminal proceedings, if the officer or director had no reasonable cause to believe his conduct was lawful. Accordingly, indemnification may be sought for liabilities arising under the Securities Act. The Underwriting Agreement for the Company's IPO contains provisions under which the Company and Blair have agreed to indemnify each other (including officers and directors) for certain liabilities, including liabilities under the Securities Act. Insofar as indemnification for liabilities arising under the Securities Act may be permitted for directors, officers and controlling persons of the Company pursuant to the foregoing provisions or otherwise, the Company has been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and may, therefore, be unenforceable. Compliance with Section 16(a) of the Exchange Act The following directors and officer have not filed updated reports pursuant to Section 16(a) of the Exchange Act: Vinit Saxena Form 5 Armin Ramel Form 5 Henry Edmunds Forms 3 and 5 John Walker Forms 3 and 5 Charles Janac Forms 3 and 5 Item 10. Executive Compensation ------- ---------------------- Compensation of Directors Members of the Board of Directors who are not employees of the Company do not currently receive cash compensation. Pursuant to the stock option plans, they are eligible for stock options. Page 38 Compensation of Executives Employment Agreements On August 30, 1994, the Company entered into employment agreements with Mr. Vinit Saxena as its President and Chief Executive Officer. Mr. Saxena's agreement is for a six-year term. Mr. Saxena is to receive a salary of $125,000 per annum, plus bonuses up to $25,000 per annum. Such compensation may be increased and bonuses may be given upon the approval of the Board of Directors of the Company. Mr. Saxena has agreed to devote his full time and efforts to his employment with the Company. He will be entitled to participate in employee benefit plans. The Company has the right to terminate either agreement for cause or as a result of death or permanent disability. Except in the case of termination for cause, upon early termination of their agreements, Mr. Saxena will be entitled to receive his salary plus fringe benefits for a period of 36 months, from the date of termination and any bonuses prorated through the date of termination, so long as he does not violate the non-disclosure and non-solicitation provisions of his agreement; provided, however, any salary and benefits to be received after termination will be reduced by any salary and benefits he receives from any successor position during the post-termination payment period. Mr. Saxena has agreed not to disclose to anyone confidential information of the Company during the term of his employment or thereafter and will not compete with the Company during the term of his employment. All work, research and results thereof, including, without limitation, inventions, processes or formulae, conceived or developed by Mr. Saxena during the term of employment which are related to the business, research, and development work or field of operation of the Company, shall be the property of the Company. The employment agreement expired on August 20, 2000. Key-Person Life Insurance The Company has obtained key-person life insurance coverage in the face amount of $2,000,000 on Mr. Saxena naming the Company as beneficiary under such policy. 1994 Stock Option Plan On August 30, 1994, the Board of Directors and the shareholders of the Company adopted and approved the 1994 Stock Option Plan. The 1994 Stock Option Plan provides for the grant of incentive stock options ("ISO's") within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the "Code"), and non-qualified stock options ("NQSO's") to certain employees, officers, directors, consultants and agents of the Company. The purpose of the 1994 Stock Option Plan is to attract and retain qualified employees, agents, consultants, officers and directors. The total number of shares of Class A Common Stock with respect to which options may be granted under the 1994 Stock Option Plan is 400,000. The shares subject to, and available under, the 1994 Stock Option Plan may consist, in whole or in part, of authorized but un-issued stock or treasury stock not reserved for any other purpose. Any shares subject to an option that terminates, expires or lapses for any reason, and any shares purchased upon exercise of an option and subsequently repurchased by the Company pursuant to the terms of the options, become available for grant under the 1994 Stock Option Plan. The 1994 Stock Option Plan is administered by the Board of Directors of the Company, which determines, in its discretion, among other things, the recipients of grants, whether a grant will consist of ISO's or NQSO's, or a combination thereof, and the number of shares of Class A Common Stock to be subject to such options. The Board may, in its discretion, delegate its power, duties and responsibilities under the 1994 Stock Option Plan to a committee consisting of two or more directors who are "non-employee directors" within the meaning of Rule 16b-3 promulgated under the Exchange Act. The exercise price for ISO's must be at least 100% of the fair market value per share of Class A Common Stock on the date of grant, as determined by the Board. Page 39 Options may be exercisable for a term determined by the Board, which may not be less than one year or greater than 10 years from the date of grant. No options may be granted under the 1994 Stock Option Plan later than 10 years after the 1994 Stock Option Plan's effective date of August 30, 1994. ISO's are not transferable other than by will or the laws of descent and distribution. NQSO's may be transferred to the optionee's spouse or lineal descendants, subject to certain restrictions. Options may be exercised during the holder's lifetime only by the holder or his or her guardian or legal representative. Options may be exercised only while the original optionee has a relationship with the Company which confers eligibility to be granted options or within 90 days after termination of such relationship with the Company, or up to six months after death or total and permanent disability. In the event the Company terminates such relationship between the original optionee and the Company for cause (as defined in the 1994 Stock Option Plan), all options granted to the optionee terminate immediately. In the event of certain basic changes in the Company, including a change in control of the Company (as defined in the 1994 Stock Option Plan), at the discretion of the Board, the Board may make certain adjustments to the outstanding stock options. The 1994 Stock Option Plan contains certain limitations applicable only to ISO's granted there under to satisfy specific provisions of the Code. For example, the aggregate fair market value, as of the date of grant, of the shares to which ISO's become exercisable for the first time by an optionee during the calendar year may not exceed $100,000. In addition, if an optionee owns more than 10% of the Company's stock at the time the individual is granted an ISO, the exercise price per share cannot be less than 110% of the fair market value per share and the term of the option cannot exceed five years. Options may be paid for in cash, by check or, in certain instances, by delivering an assignment of shares of Class A Common Stock having a value equal to the option price, or any combination of the foregoing, as stipulated in the option agreement entered into between the Company and the optionee. At the discretion of the Board, the Company may loan to the optionee some or all of the purchase price of the shares acquired upon exercise of an option granted under the 1994 Stock Option Plan. The Board may modify, suspend or terminate the 1994 Stock Option Plan; provided, however, that certain material modifications affecting the 1994 Stock Option Plan must be approved by the shareholders, and any change in the 1994 Stock Option Plan that may adversely affect an options rights under an option previously granted under the 1994 Stock Option Plan requires the consent of the optionee. 1996 Stock Option Plan On June 28, 1996, the Board of Directors and the shareholders of the Company adopted and approved the 1996 Stock Option Plan. The 1996 Stock Option Plan provides for the grant of incentive stock options ("ISO's") within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the "Code"), and non-qualified stock options ("NQSO's") to certain employees, officers, directors, consultants and agents of the Company. The purpose of the Stock Option Plan is to attract and retain qualified employees, agents, consultants, officers and directors. The terms of this plan are substantially similar to the 1994 Stock Option Plan. The total number of shares of Class A Common Stock with respect to which options may be granted under the 1996 Stock Option Plan is 250,000. The shares subject to, and available under, the 1996 Stock Option Plan may consist, in whole or in part, of authorized but un-issued stock or treasury stock not reserved for any other purpose. Any shares subject to an option that terminates, expires or lapses for any reason, and any shares purchased upon exercise of an option and subsequently repurchased by the Company pursuant to the terms of the options, become available for grant under the 1996 Stock Option Plan. Page 40 Options Granted As of January 1, 2001, the Company had outstanding 1,468,361 options to purchase shares of Class A Common Stock issued but during the year 725,058 expired. The board has not extended the time or granted replacement option. In 2001 the Company granted 54,000 of options to two consultants. Other Outstanding Stock Options In addition to the shares of Class A Common Stock with respect to which options may be granted under the Company's Stock Option Plans, the Board of Directors of the Company granted nonqualified options to various investors and current and former directors, employees, and consultants to the Company of which one option remains outstanding to purchase 314 shares of Class B Common Stock at an exercise price of $3.01 per share, which is now fully vested. 401(k) Profit Sharing Plan In 1995, the Company adopted a 401(k) profit sharing plan under which employees may defer a portion of their salary. The Plan was terminated effected December 31, 2001. Summary Compensation Table The following table sets forth all compensation paid for the past three fiscal years to the chief executive officer and to executive officers whose cash compensation exceeded $100,000 during the fiscal year ended December 31, 1999.
Annual Compensation L-T Compensation ------------------- ---------------- (a) (b) (c) (d) (g) Securities underlying Name and Principal Position Year Salary (1) Bonus Options/SAR's(#) Vinit Saxena, President, Chief 2001 $135,147 $0 0 Executive Officer and Chief Financial Officer 2000 $134,327 $0 0 1999 $133,906 $0 0 ----------------------------------------------------------
--------------- (1) Includes health insurance costs for Mr. Saxena and his family in the amounts of $7,700, $7,596, and $10,147 during 1999, 2000 and 2001, respectively. Mr. Saxena `s 2001 compensation includes $57,292 paid and $67,708 accrued pay. Page 41 Aggregated Option/SAR Exercises in Last Fiscal Year 2000 and 2001 Fiscal Year-End Option/SAR Values
(a) (b) (c) (d) (e) Number of Securities Value of Unexercised In- Shares Value Underlying Unexercised the-Money Options/SAR's Acquired on Realized Options/SAR's at FY-End at FY End Name Exercise (#) ($) Unexercisable Exercisable Unexercisable Exercisable --------------------- ------------ --- ------------- ----------- ------------- ----------- Vinit Saxena 0 $0 0 218,324 $0 $0 President, Chief Executive Officer, Chief Financial Officer & Chairman of the Board
--------------- In the last three fiscal years, the Company has not paid or awarded any other stock awards, options, stock appreciation rights, or other long-term incentive plan compensation to the executive officers named above. Page 42 Item 11. Security Ownership of Certain Beneficial Owners and Management. ------- -------------------------------------------------------------- The following table sets forth certain information as to the beneficial ownership of the Company's Common Stock as of March 20, 2002 of: (i) each person who is known by the Company to own beneficially more than 5% of the outstanding shares of the Company's Class A and Class B Common Stock, (ii) each director of the Company and (iii) all officers and directors of the Company as a group.
--------------------------------------------------------------------------------------------------------- Name and Address of Bene- Number of Shares of Common Percentage of Common Stock Percentage of fician Owner or Number in Stock Beneficially Beneficially Owned (1) Voting Power Group Owned(1) --------------------------------------------------------------------------------------------------------- Vinit Saxena (2) 662,690 6% 13% 30689 Huntwood Avenue Hayward, CA 94544 --------------------------------------------------------------------------------------------------------- Michael Schneider (3) 852,930 7% 15% 150 Encinal Avenue Atherton, CA 94025 --------------------------------------------------------------------------------------------------------- K. Charles Janac (4) 1,151,549 10% 8% 651 River Oaks Parkway San Jose, CA 95134 --------------------------------------------------------------------------------------------------------- Eliezer Sternheim, Ph.D. (5) 572,916 5% 4% 46871 Bayside Parkway Fremont, CA 94538 --------------------------------------------------------------------------------------------------------- Henry N. Edmunds (6) 190,218 2% 1% 11096 Caminito Alvarez San Diego, CA 92126-5710 --------------------------------------------------------------------------------------------------------- Armin Ramel, Ph.D. (7) 127,688 1% *% 4 Sandstone Portola Valley, CA 94028 --------------------------------------------------------------------------------------------------------- Joseph R. Mallon (8) 112,000 1% *% 5 Tanager Lane Morristown, NJ 07960 --------------------------------------------------------------------------------------------------------- John Walker (9) 980 Covington Road 50,000 *% *% Los Altos, CA 94024 --------------------------------------------------------------------------------------------------------- Jon Salquist (10) 960,000 8% 7% 2725 N.W. Circle A Drive Portland, OR 97229 --------------------------------------------------------------------------------------------------------- All directors and executive 3,254,145 26% 31% officers as a group (6 in number) --------------------------------------------------------------------------------------------------------- * = less than 1%.
Page 43 (1) Except as otherwise indicated, each of the parties listed has sole voting and investment power with respect to all shares of Common Stock indicated below. Beneficial ownership is calculated in accordance with Rule 13d-3(d) under the Securities Exchange Act of 1934, as amended. We have two classes of Common Stock outstanding, Class A and Class B. Class E Common Stock became subject to redemption on March 31, 2000 and a notice of redemption has declared June 15, 2000 to be the effective date of the redemption and was not included in the above calculations. (2) Amounts and percentages include (i) 296,281 shares of Class B Common Stock which is convertible into one share of Class A Common Stock; (each share of Class B Common Stock has five votes per share); (ii) 62,369 shares of Class A Common Stock; (iii) options to purchase 218,324 shares of Class A Common Stock; (iv) 57,813 shares of Class A Common Stock and options to purchase 22,000 shares of Class A Common Stock, held by Renu Saxena, an employee of the Company and the spouse of Vinit Saxena; and (v) 5,903 shares of Class B Common Stock owned jointly by Renu Saxena and Rakesh Chabra (Renu Saxena's brother). (3) Amounts and percentages include 337,483 shares of Class B Common Stock and 515,447 shares of Class A Common Stock. (4) Amounts and percentages include 876,882 shares of Class A Common Stock and warrants to purchase 274,667 shares of Class A Common Stock. (5) Amounts and percentages include 520,833 shares of Class A Common Stock and warrants to purchase 52,083 shares of Class A Common Stock. (6) Amounts and percentages include (i) options to purchase 40,000 shares of Class A Common Stock granted under our Stock Option Plans; (ii) 10,000 Class C Warrants to purchase Class A Common Stock, (iii) 127,471 shares of Class A Common Stock and (iv) warrants to purchase 12,747 shares of Class A Common Stock. (7) Amounts and percentages include (i) options to purchase 61,747 shares of Class A Common Stock granted under our Stock Option Plans; (ii) 59,946 shares of Class A Common Stock; and (iii) warrants to purchase 5.995 shares of Class A Common Stock. (8) Amounts and percentages include 72,000 shares of Class A Common Stock and options to purchase 40,000 shares of Class A Common Stock granted under our Stock Option Plans. (9) Amounts and percentages include options to purchase 40,000 shares of Class A Common Stock granted under our Stock Option Plans and an option to purchase 10,000 shares of Class A Common Stock. (10) Amounts and percentages include 800,000 shares of Class A Common Stock and warrants to purchase 160,000 shares of Class A Common Stock. Item 12. Certain Relationships and Related Transactions. ------- ---------------------------------------------- Grant of stock options The following directors and officers were granted stock options:
---------------------------------------------------------------------------------------------------- Grant Date Expire Date Option Shares Exercise $/share ---------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- John Walker, Director 12/1/98 12/01/02 40,000 0.50 Joe Mallon, Director 12/1/99 12/01/03 40,000 0.72 John Walker, Director 2/4/00 01/01/05 10,000 0.75 K. Charles Janac, Director 07/10/00 07/09/05 40,000 0.78 ----------------------------------------------------------------------------------------------------
Grants of warrants: Mr. Jon Salquist, a director of the company, was granted 80,000 Class A warrants at $0.25 exercise price that will expire by August 20, 2006. Page 44 The following officer and directors purchased Bridge Notes and related Class C warrants from us pursuant to our November 3, 1997 private placement: Dr. Kris Venkat $10,000 Dr. Henry N. Edmunds $10,000 Dr. Quirin Miranda $25,000 Drs. Venkat and Miranda were repaid in August 1998 and Dr. Edmunds converted his note to Class A Common Stock on December 15, 1998. Shareholder notes In May 1997, we borrowed $100,000 from a shareholder, payable with interest at 9.5% per annum and was due March 1, 1999. In June 1997, we borrowed $25,000 from Dr. Armin Ramel, a director and shareholder of the Company, payable with interest at 9.5% per annum and such debt was converted to Class A Common Stock on December 15, 1998. In June 1998, we borrowed $125,000 from H. Michael Schneider, a former director and shareholder of the Company, payable with interest at 9.5% per annum, and such debt was converted into Class A Common Stock on December 15, 1998. In August 1998, we borrowed $30,000 from Robert Leach, a former director and shareholder of the Company, payable with interest at 9.5% per annum, and $15,000 of such debt was converted into Class A Common Stock on December 15, 1998 . In March 2000, Mr. Leach converted $10,000 of his Note payable into 11,500 shares of Class A Common Stock and the balance of $8,958 in principal and accrued interest was paid in July 2000. In December 2000, we borrowed $50,000 from H. Michael Schneider, a former director and shareholder of the Company. In 2001 we borrowed an aggregate of $130,000 from H. Michael Schneider. Series A Preferred Stock On September 1, 1998, we sold 175,439 shares of Series A Preferred Stock. All of the shares of Series A Preferred Stock were sold to Anchor Products Limited of Hamilton, New Zealand ("Anchor"). The acquisition of Series A Preferred Stock by Anchor was consummated in connection with the execution of a Commercial License Agreement between us and Anchor, whereby the Company licensed to Anchor a technology that isolates proteins from whey, a low value cheese by-product. The shares of Series A Preferred Stock were sold for cash in the aggregate amount of $500,000 ($2.85 per share). There were no underwriting discounts or commissions paid in connection with the transaction. The shares of Series A Preferred Stock were sold pursuant to exemptions from registration under section 4(2) and Regulation S under the Securities Act of 1933, in a transaction that was not publicly offered. Anchor is a New Zealand corporation. Our Series A Preferred Stock provides for both a 7.5% dividend and liquidation preferences. The dividend is payable from time to time at the election of our Board of Directors of the Company subject to our retaining sufficient earnings and profits. The Preferred Stock is also convertible on or before September 30, 2000 into Class A Common Stock, at the conversion rate of $2.86 per share. On any voluntary or involuntary liquidation, dissolution or winding-up of the Company, the holders of series A Preferred Shares shall receive, out of the assets of the Company, the sum of $2.86 per Series A Preferred Share, plus an amount equal to any dividend accrued and unpaid on those series A Preferred Shares, before any payment shall be made or any assets distributed to the holders of Common Stock. The Series A Preferred Shares shall be redeemable at the option of the holders of the Series A Preferred Shares commencing September 30, 2003 and expiring December 31, 2008, at the cash price of $2.86 per share, plus any accrued and unpaid dividends on the Series A Page 45 Preferred Shares which are redeemed. In addition, each share of Series A Preferred Stock shall be automatically converted into one (1) share of Class A Common Stock, if not previously redeemed, on January 1, 2009, or at any time the closing bid price per share of the Company's Class A Common Stock shall average at least $3.86 per share over ninety (90) consecutive trading days prior to January 1, 2004. The conversion ratio for the Series A Preferred Stock shall be adjusted in the event of recapitalization, stock dividend, or any similar event affecting the Class A Common Stock. Anchor may require us to immediately redeem the preferred shares in the event of certain covenant breaches of the license agreement by us. We are currently in compliance with all such covenants and do not anticipate any future material breach. Conversion of Debt On December 15, 1998, we issued to Charles Janac 781,457 shares of Class A Common stock and Warrants to purchase 234,667 shares of Class A Common Stock at $0.46875 per share (expiring August 19, 2003) in exchange for the conversion of $366,308 of notes and accrued interest held by Mr. Janac. On December 15, 1998, we issued to Eliezer Sternheim 520,833 shares of Class A Common stock and Warrants to purchase 52,083 shares of Class A Common Stock at $0.48 per share (expiring December 15, 2003) in exchange for $250,000 cash. On December 15, 1998, we issued to Armin Ramel, a director of the Company, 59,946 shares of Class A Common stock and Warrants to purchase 5,995 shares of Class A Common Stock at $0.48 per share (expiring December 15, 2003) in exchange for the conversion of $28,774 of notes and accrued interest held by Mr. Ramel. On December 15, 1998, we issued to Henry Edmunds, a director of the Company, 127,471 shares of Class A Common stock and Warrants to purchase 12,747 shares of Class A Common Stock at $0.48 per share (expiring December 15, 2003) in exchange for $50,000 cash and the conversion of $11,186 of notes and accrued interest held by Mr. Edmunds. On December 15, 1998, we issued to Michael Schneider, a former director and more than 5% shareholder of the Company, 275,614 shares of Class A Common stock and Warrants to purchase 27,561 shares of Class A Common Stock at $0.48 per share (expiring December 15, 2003) in exchange for the conversion of $132,294 of notes and accrued interest held by Mr. Schneider. On December 15, 1998, we issued to Robert Leach, a former director of the Company, 32,475 shares of Class A Common stock and Warrants to purchase 3,248 shares of Class A Common Stock at $0.48 per share (expiring December 15, 2003) in exchange for the conversion of $15,588 of notes and accrued interest held by Mr. Leach. On March 15, 1999, we issued to Vinit Saxena, Chief Operating officer, 62,369 shares of Class A Common Stock at $0.48 per share in exchange for $29,937 of deferred salary. On March 15, 1999, we issued Sanjeev Saxena, an employee and brother of Vinit Saxena, 35,938 shares of Class A Common Stock at $0.48 per share in exchange for $17,250 of deferred salary. On March 15, 2000, we issued to Renu Saxena, an employee and spouse of Vinit Saxena, 21,875 shares of Class A Common Stock at $0.48 per share in exchange for $10,500 of deferred salary. On December 15, 1999, we issued to Koyah Leverage Partners 266,667 shares of Class A Common Stock at $0.75 per share in exchange for $200,000 cash. Page 46 On December 15, 1999, we issued to Koyah Partners LP 66,667 shares of Class A Common Stock at $0.75 per share in exchange for $50,000 cash. On December 15, 1999, we issued to Joseph R. Mallon 72,000 shares of Class A Common Stock at $0.75 per share in exchange for $54,000 cash. On December 15, 1999, we issued to Summit Securities, Inc. 333,333 shares of Class A Common Stock at $0.75 per share in exchange for $250,000 cash. On August 18, 1999, we received proceeds from convertible note payable from H. Michael Schneider, former director and shareholder of $260,000 with interest at 9.5% per annum. In March 2000, Mr. Schneider converted $130,000 of the note payable into 173,333 shares of Class A Common Stock. The remaining balance of $130,000 was paid in April 2000. On March 31, 2000, Private Situations Equity Fund, L.P. purchased 1,333,334 shares of Class A Common Stock at $0.75 per share and entered into a registration rights agreement covering those shares. In addition, we must issue 13,333 shares of Class Common Stock to Special Situations for each month after July 15, 2000 in which a registration statement covering their shares has not been declared effective by the Securities and Exchange Commission. On the day the Securities and Exchange Commission declared the registration effective 26,666 additional shares have been issued. Crown Point Securities, as placement agent in connection with a private placement of Class A Common Stock completed in March 2000 received commissions and a warrant to purchase 272,720 shares of Class A Common Stock at an exercise price of $0.50 per share having an expiration date of March 31, 2005. Item 13. Exhibits and Reports on Form 8-K ------- -------------------------------- Each exhibit identified below is filed as part of this report. Exhibits incorporated by reference to a prior filing are designated by a numbered footnote. Exhibits designated with a "+" constitute a management contract or compensatory plan or arrangement required to be filed as an exhibit to this report pursuant to Item 13 of Form 10-KSB. (a) Exhibits. -------- The following exhibits are filed as part of this Report: 1.1(1) Form of Underwriting Agreement 3.1(1) Restated Articles of Incorporation of the Company, as amended to date 3.2(2) Restated Bylaws, as amended to date. 3.3(6) Certificate of Determination 4.1(1) Form of Warrant Agreement among the Company, the Underwriter and American Stock Transfer Company, including Forms of Class A Warrant Certificates and Class B Warrant Certificates 4.2(1) Form of Unit Option Agreement between the Company and the Underwriter 4.3(1) Form of Specimen Class A Common Stock Certificate Page 47 4.4(1) Form of Specimen Class B Common Stock Certificate 4.5(1) Form of Specimen Class E Common Stock Certificate 4.6(1) Bridge Warrant Agreement, including forms of Bridge Warrant Certificate 4.7(7) Warrant Agreement with Charles Janac 4.8 Registration Rights Agreement with Special Situations Private Equity Fund, L.P. dated March 31, 2000 10.1(2) Lease dated July 3, 1995 between Hayward Business Park, Inc. and the Company. 10.2(1)+ Employment Agreement between the Company and Vinit Saxena effective September 1, 1994 10.3(1)+ Employment Agreement between the Company and Q. R. Miranda effective September 1, 1994 10.4(1) Form of Indemnification Agreement between the Company and each director and officer of the Company 10.5(1) Convertible Promissory Notes and Warrants 10.6(1)+ 1994 Stock Option Plan 10.7(3) Master Purchasing Agreement with Thermax Limited dated April 23, 1996 10.8(4)+ 1996 Stock Option Plan 10.9(7) Convertible Secured Promissory Note issued by the Company to Charles Janac 10.10(7) Security Agreement with Charles Janac 10.11(7) Patent and Trademark Mortgage 16.1(5) Letter on Change in Certifying Accountant. 23 Consent of Bedinger & Company Page 48 27 Financial Data Schedule ----------------------------------------------------- (1) These exhibits which are incorporated herein by reference were previously filed by the Company as exhibits to its Registration Statement on Form SB-2 and Amendments Nos. 1, 2, 3, 4 and 5 and Post Effective No. 1 (File No. 33-86888). (2) These exhibits which are incorporated herein by reference were previously filed by the Company as exhibits to its Quarterly Report on Form 10-QSB for the quarter ended September 30, 1995. (3) These exhibits which are incorporated herein by reference were previously filed by the Company as exhibits to its Quarterly Report on Form 10-QSB for the quarter ended March 31, 1996. (4) These exhibits which are incorporated herein by reference were previously filed by the Company as exhibits to its Quarterly Report on Form 10-QSB for the quarter ended June 30, 1996. (5) These exhibits which are incorporated herein by reference were previously filed by the Company as exhibits to its Report on Form 8-K dated January 13, 1998. (6) These exhibits which are incorporated herein by reference were previously filed by the Company as exhibits to its Report on Form 8-K dated September 4, 1998. (7) These exhibits which are incorporated herein by reference were previously filed by the Company as exhibits to its Quarterly Report on Form 10-QSB for the quarter ended September 30, 1998. Exhibits not listed above have been omitted because they are inapplicable or because the required information is given in the financial statements or notes thereto. (b) Reports on Form 8-K. ------------------- No 8-K report was filed in 2001. Page 49 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized, on this 13th day of April 2001. SEPRAGEN CORPORATION By: /s/ VINIT SAXENA ------------------------------------- Vinit Saxena Chief Executive Officer and President Pursuant on the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons in the capacities and on the dates indicated. /s/ VINIT SAXENA April 5, 2002 ------------------------------ Vinit Saxena (Principal Executive Officer) Chief Executive Officer, President, Chairman of the Board, and Director /s/ ARMIN RAMEL April 5, 2002 ------------------------------ Armin Ramel Director and Secretary /s/ HENRY N. EDMUNDS April 5, 2002 ------------------------------ Henry N. Edmunds Director and Chief Financial Officer /s/ JON SALQUIST April 5, 2002 ------------------------------ Jon Salquist Director /s/ JOHN WALKER April 5, 2002 ------------------------------ John Walker Director /s/ JOSEPH R. MALLON, JR. April 5, 2002 ------------------------------ Joseph R. Mallon, Jr. Director Page 50 INDEX TO EXHIBITS Exhibits incorporated by reference to a prior filing are designated by a numbered footnote. Exhibits designated with a "+" constitute a management contract or compensatory plan or arrangement required to be filed as an exhibit to this report pursuant to Item 13 of Form 10-KSB. No. Description ------- ----------------------------------------------------------------------- 1.1(1) Form of Underwriting Agreement 3.1(1) Restated Articles of Incorporation of the Company, as amended to date 3.2(2) Restated Bylaws, as amended to date. 3.3(6) Certificate of Determination Series A Preferred Stock 4.1(1) Form of Warrant Agreement among the Company, the Underwriter and American Stock Transfer Company, including Forms of Class A Warrant Certificates and Class B Warrant Certificates 4.2(1) Form of Unit Option Agreement between the Company and the Underwriter 4.3(1) Form of Specimen Class A Common Stock Certificate 4.4(1) Form of Specimen Class B Common Stock Certificate 4.5(1) Form of Specimen Class E Common Stock Certificate 4.6(1) Bridge Warrant Agreement, including forms of Bridge Warrant Certificate 4.7(7) Warrant Agreement with Charles Janac 4.8 Registration Rights Agreement with Special Situations Private Equity Fund, L.P. dated March 31, 2000 10.1(2) Lease dated July 3, 1995 between Hayward Business Park, Inc. and the Company. 10.2(1)+ Employment Agreement between the Company and Vinit Saxena effective September 1, 1994 10.3(1)+ Employment Agreement between the Company and Q. R. Miranda effective September 1, 1994 10.4(1) Form of Indemnification Agreement between the Company and each director and officer of the Company 10.5(1) Convertible Promissory Notes and Warrants 10.6(1)+ 1994 Stock Option Plan 10.7(3) Master Purchasing Agreement with Thermax Limited dated April 23, 1996 10.8(4)+ 1996 Stock Option Plan 10.9(7) Convertible Secured Promissory Note issued by the Company to Charles Janac 10.10(7) Security Agreement with Charles Janac 10.11(7) Patent and Trademark Mortgage 16.1(5) Letter on Change in Certifying Accountant. 23 Consent of Bedinger & Company Page 51 27 Financial Data Schedule ----------------------- (1) These exhibits which are incorporated herein by reference were previously filed by the Company as exhibits to its Registration Statement on Form SB-2 and Amendments Nos. 1, 2, 3, 4 and 5 and Post Effective No. 1 (File No. 33-86888). (2) These exhibits which are incorporated herein by reference were previously filed by the Company as exhibits to its Quarterly Report on Form 10-QSB for the quarter ended September 30, 1995. (3) These exhibits which are incorporated herein by reference were previously filed by the Company as exhibits to its Quarterly Report on Form 10-QSB for the quarter ended March 31, 1996. (4) These exhibits which are incorporated herein by reference were previously filed by the Company as exhibits to its Quarterly Report on Form 10-QSB for the quarter ended June 30, 1996. (5) These exhibits which are incorporated herein by reference were previously filed by the Company as exhibits to its Report on Form 8-K dated January 13, 1998. (6) These exhibits which are incorporated herein by reference were previously filed by the Company as exhibits to its Report on Form 8-K dated September 4, 1998. Page 52